<SEC-DOCUMENT>0001104659-22-044376.txt : 20220411
<SEC-HEADER>0001104659-22-044376.hdr.sgml : 20220411
<ACCEPTANCE-DATETIME>20220408204301
ACCESSION NUMBER:		0001104659-22-044376
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220408
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220411
DATE AS OF CHANGE:		20220408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		22818314

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2212156d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:rmti="http://rockwellmed.com/20220408">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_rmti_rockwellmed.com_20220408 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20220408_20220408 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001041024 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityCentralIndexKey">0001041024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rmti-20220408.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-08to2022-04-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-08</xbrli:startDate>
        <xbrli:endDate>2022-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90E_edei--DocumentType_c20220408__20220408_zcbYSwyvLaIf"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or
15(d)&#160;<br />
of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <b>&#160;<span id="xdx_90A_edei--DocumentPeriodEndDate_c20220408__20220408_zXmiAB7op5ob"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 8, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report<br />
(Date of earliest event reported)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20220408__20220408_zFE7O6SpqDc"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityRegistrantName">Rockwell Medical, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding: 1.5pt; vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20220408__20220408_zD5y9KwIzvV"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.5pt; vertical-align: bottom; font-size: 10pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityFileNumber_c20220408__20220408_zZfgsAUXAA8d"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityFileNumber">000-23661</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.5pt; vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20220408__20220408_z04Ks0ClPIMj"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityTaxIdentificationNumber">38-3317208</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.5pt; vertical-align: top; text-align: center"><b>(State or other jurisdiction <br />
    of incorporation)</b></td>
    <td style="padding: 1.5pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission
    <br />
    File Number)</b></span></td>
    <td style="padding: 1.5pt; vertical-align: top; text-align: center"><b>(IRS Employer<br />
    Identification No.)</b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220408__20220408_zIqJOHiimNNg"><b><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityAddressAddressLine1">30142
S. Wixom Road</ix:nonNumeric></b></span><b>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20220408__20220408_z7RuqMQjWRKh"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityAddressCityOrTown">Wixom, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20220408__20220408_zXkRF6X1D6Dj"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Michigan</ix:nonNumeric>
</span></ix:nonNumeric></span></b><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20220408__20220408_zcisufWc9Nyf"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:EntityAddressPostalZipCode">48393</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices, including
Zip Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_903_edei--CityAreaCode_c20220408__20220408_zAthq468J01"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:CityAreaCode">248</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20220408__20220408_zVWRFPNAT7sa"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:LocalPhoneNumber">960-9009</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form
8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20220408__20220408_zv1qSf07Vbra"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20220408__20220408_znADOcsWKwMd"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20220408__20220408_z0EzgtiFrcK8"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20220408__20220408_z7FHiVOGry1g"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-bottom: 1pt; padding-left: 1.5pt">Title&#160;of&#160;each&#160;class</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-bottom: 1pt; padding-left: 1.5pt">Trading&#160;<br />
Symbol (s)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; padding-left: 1.5pt">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which registered</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_90C_edei--Security12bTitle_c20220408__20220408_zWaebEesg8Hf"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:Security12bTitle">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_90A_edei--TradingSymbol_c20220408__20220408_zCALe77hhfHc"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" name="dei:TradingSymbol">RMTI</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_907_edei--SecurityExchangeName_c20220408__20220408_zWjSUcNYhifj"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Market</ix:nonNumeric></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20220408__20220408_zPkZFCKHVbwi"><ix:nonNumeric contextRef="From2022-04-08to2022-04-08" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.
</span><span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Item 1.01</span></b></span></td><td><b><span style="text-decoration: underline">Entry into a Material Definitive Agreement.</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&#160;8, 2022, Rockwell Medical,&#160;Inc.
(the &#8220;<b><i>Company</i></b>&#8221;) entered into a sales agreement (the &#8220;<b>Sales Agreement</b>&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. (the &#8220;<b><i>Agent</i></b>&#8221;), pursuant to which the Company may offer and sell from time to time shares of Company&#8217;s
common stock, par value $0.0001 (the &#8220;<b><i>Shares</i></b>&#8221;), through the Agent. The offering and sale of up to $12,200,000
of the Shares has been registered under the Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;), pursuant
to the Company&#8217;s Registration Statement on Form&#160;S-3 (File No.&#160;333-259923) (the &#8220;<b><i>Registration Statement</i></b>&#8221;),
which was originally filed with the Securities and Exchange Commission (&#8220;<b><i>SEC</i></b>&#8221;) on September&#160;30, 2021 and
declared effective by the SEC on October&#160;8, 2021, the base prospectus contained within the Registration Statement, and a prospectus
supplement that was filed with the SEC on April&#160;8, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of the Shares, if any, pursuant to the Sales
Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4)&#160;promulgated
under the Securities Act, including sales made directly on or through the Nasdaq Capital Market or on any other existing trading market
for our common stock. The Company has no obligation to sell any of the Shares under the Sales Agreement, and may at any time suspend offers
under the Sales Agreement or terminate the Sales Agreement. The Agent will act as sales agent and will use commercially reasonable efforts
to sell on the Company&#8217;s behalf all of the Shares requested to be sold by the Company, consistent with its normal trading and sales
practices, on mutually agreed terms between the Agent and the Company. The Company intends to use the proceeds of the offering for working
capital and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sales Agreement contains customary representations,
warranties and agreements by the Company, as well as indemnification obligations of the Company for certain liabilities under the Securities
Act. Under the terms of the Sales Agreement, the Company will pay the Agent a commission of up to 3.0% of the gross sales price of the
Shares sold through it under the Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by the Agent
in connection with the offering. The Sales Agreement may be terminated by the Agent or the Company at any time upon notice to the other
party, as set forth in the Sales Agreement, or by the Agent at any time in certain circumstances, including the occurrence of a material
and adverse change in the Company&#8217;s business or financial condition that makes it impractical or inadvisable to market the shares
or to enforce contracts for the sale of the Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form&#160;8-K shall not
constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the opinion of Gibson, Dunn&#160;&amp;
Crutcher LLP relating to the validity of the shares of common stock that may be sold pursuant to the Sales Agreement is filed herewith
as Exhibit&#160;5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description of the material terms of the Sales
Agreement is not intended to be complete and is qualified in its entirety by reference to the Sales Agreement, which is filed herewith
as Exhibit&#160;1.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="padding-left: 10pt; text-indent: -10pt; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Item 9.01</span></b></span></td>
  <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Financial Statements and Exhibits</span></b></span><b>.</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;<i>Exhibits</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">EXHIBIT&#160;INDEX</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="padding: 0.25pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 88%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2212156d2_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2212156d2_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    Agreement, dated April&#160;8, 2022, between Rockwell Medical,&#160;Inc. and Cantor Fitzgerald&#160;&amp; Co.</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2212156d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2212156d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Gibson, Dunn&#160;&amp; Crutcher LLP</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2212156d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2212156d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Gibson, Dunn&#160;&amp; Crutcher LLP (contained in Exhibit&#160;5.1)</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File, formatted in INline XBRL and included as Exhibit&#160;101.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline">SIGNATURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 50%">&#160;</td>
  <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ROCKWELL MEDICAL,&#160;INC.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 50%">&#160;</td>
  <td style="text-align: justify; width: 5%">By:</td>
  <td style="border-bottom: Black 1pt solid; text-align: justify; width: 45%">/s/ Russell Skibsted</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April&#160;8, 2022 </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 50%">&#160;</td>
  <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </span></td>
  <td style="width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell Skibsted</span></td></tr>
</table>


<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 50%">&#160;</td>
  <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
  <td style="width: 45%"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi05/dNGdFhWxihQRt0ObymA7KZnx70je0rFFDIGQvPflCTESa1rpBhnOiyKHI7ZdoxxCgTUymhK9I9tsU/CzwIu2jpVx/foDM/IMemY6jkt/7513bbFKQc4mMplEEmSSxiHMdyL46hmZWldonFYNKFPBgaljjU7xa/hwVE8y1L76pBOy1WRSCMdykN8QyTCCPd3Vg/hqIc8zEYz6CsSa6dZ9Y27WUQvLBlufZQf038EH0vxJBg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2212156d2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ROCKWELL
MEDICAL,&nbsp;INC.</B></FONT><BR>
Shares of Common Stock&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(no par value per share)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Controlled Equity Offering<SUP>SM</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Sales Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">April&nbsp;8, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cantor Fitzgerald&nbsp;&amp; Co.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">499 Park Avenue&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">Rockwell Medical,&nbsp;Inc.,
a Delaware corporation (the &#8220;<B><U>Company</U></B>&#8221;), confirms its agreement (this &#8220;<B><U>Agreement</U></B>&#8221;)
with Cantor Fitzgerald&nbsp;&amp; Co. (the &#8220;<B><U>Agent</U></B>&#8221;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><U>Issuance and Sale of Shares</U>. The Company agrees that, from time to time during the term of this
Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent, shares of common stock
(the &#8220;<B><U>Placement Shares</U></B>&#8221;) of the Company, no par value per share (the &#8220;<B><U>Common Stock</U></B>&#8221;);
<I>provided</I>, <I>however</I>, that in no event shall the Company issue or sell through the Agent such number or dollar amount of Placement
Shares that would (a)&nbsp;exceed the number or dollar amount of shares of Common Stock registered on the effective Registration Statement
(as defined below) pursuant to which the offering is being made, (b)&nbsp;exceed the number of authorized but unissued shares of Common
Stock (less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise
reserved from the Company&#8217;s authorized capital stock), (c)&nbsp;exceed the number or dollar amount of shares of Common Stock permitted
to be sold under Form&nbsp;S-3 (including General Instruction I.B.6 thereof, if applicable) or (d)&nbsp;exceed the number or dollar amount
of shares of Common Stock for which the Company has filed a Prospectus Supplement (as defined below) (the lesser of (a), (b), (c)&nbsp;and
(d), the &#8220;<B><U>Maximum Amount</U></B>&#8221;). Notwithstanding anything to the contrary contained herein, the parties hereto agree
that compliance with the limitations set forth in this <U>Section&nbsp;1</U> on the amount of Placement Shares issued and sold under this
Agreement shall be the sole responsibility of the Company and that the Agent shall have no obligation in connection with such compliance;
<I>provided</I>, that the Agent follows, in all material respects, the trading instructions provided pursuant to any Placement Notice
(as defined below). The offer and sale of Placement Shares through the Agent will be effected pursuant to the Registration Statement (as
defined below) filed by the Company and declared effective by the Securities and Exchange Commission (the &#8220;<B><U>Commission</U></B>&#8221;)
on October&nbsp;8, 2021, although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement
to issue Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The Company has filed,
in accordance with the provisions of the Securities Act of 1933, as amended (the &#8220;<B><U>Securities Act</U></B>&#8221;), and
the rules&nbsp;and regulations thereunder (the &#8220;<B><U>Securities Act Regulations</U></B>&#8221;), with the Commission a
registration statement on Form&nbsp;S-3 (File No.&nbsp;333-259923), including a base prospectus, relating to certain securities,
including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the
Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the
 &#8220;<B><U>Exchange Act</U></B>&#8221;), and the rules&nbsp;and regulations thereunder. The Company has prepared a prospectus or a
prospectus supplement to the base prospectus included as part of the registration statement, which prospectus or prospectus
supplement relates to the Placement Shares to be issued from time to time by the Company (the &#8220;<B><U>Prospectus
Supplement</U></B>&#8221;). The Company will furnish to the Agent, for use by the Agent, copies of the prospectus included as part
of such registration statement, as supplemented, by the Prospectus Supplement, relating to the Placement Shares to be issued from
time to time by the Company. The Company may file one or more additional registration statements from time to time that will contain
a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be a Prospectus Supplement), with
respect to the Placement Shares. Except where the context otherwise requires, such registration statement(s), as any of them may be
amended from time to time, including all documents filed as part thereof or incorporated by reference therein, and including any
information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to
Rule&nbsp;424(b)&nbsp;under the Securities Act Regulations or deemed to be a part of such registration statement(s)&nbsp;pursuant to
Rule&nbsp;430B of the Securities Act Regulations, is herein called the &#8220;<B><U>Registration Statement</U></B>.&#8221; The base
prospectus or base prospectuses, including all documents incorporated therein by reference, included in the Registration Statement,
as it may be supplemented, if necessary, by the Prospectus Supplement, in the form in which such prospectus or prospectuses and/or
Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the
Securities Act Regulations, together with any then issued Issuer Free Writing Prospectus(es), is herein called the
 &#8220;<B><U>Prospectus</U></B>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">Any reference herein to the
Registration Statement, any Prospectus Supplement, Prospectus or any Issuer Free Writing Prospectus (as defined below) shall be deemed
to refer to and include the documents, if any, incorporated by reference therein (the &#8220;<B><U>Incorporated Documents</U></B>&#8221;),
including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference
herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement,
any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the filing of
any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the date of the Prospectus
Supplement, Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes
of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed
to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or
if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &#8220;<B><U>EDGAR</U></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><U>Placements</U>. Each time that the Company wishes to issue and sell Placement Shares hereunder (each,
a &#8220;<B><U>Placement</U></B>&#8221;), it will notify the Agent by email notice (or other method mutually agreed to by the parties)
of the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number
of Placement Shares that may be sold in any one Trading Day (as defined below) and any minimum price below which sales may not be made
(each such notice, a &#8220;<B><U>Placement Notice</U></B>&#8221;), the form of which is attached hereto as <U>Schedule 1</U>. The Placement
Notice shall originate from any of the individuals from the Company set forth on <U>Schedule 3</U> (with a copy to each of the other individuals
from the Company listed on such schedule), and shall be addressed to each of the individuals from the Agent set forth on <U>Schedule 3</U>,
as such <U>Schedule 3</U> may be amended from time to time. The Placement Notice shall be effective unless and until (i)&nbsp;the Agent
declines to accept the terms contained therein for any reason, in its sole discretion, within two (2)&nbsp;Business Days (as defined below)
of receipt of such Placement Notice, (ii)&nbsp;the entire amount of the Placement Shares thereunder have been sold, (iii)&nbsp;the Company
suspends or terminates the Placement Notice or (iv)&nbsp;this Agreement has been terminated under the provisions of <U>Section&nbsp;12</U>.
The amount of any discount, commission or other compensation to be paid by the Company to the Agent in connection with the sale of the
Placement Shares shall be calculated in accordance with the terms set forth in <U>Schedule 2</U>. It is expressly acknowledged and agreed
that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless
and until the Company delivers a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms
set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement
and the terms of a Placement Notice, the terms of the Placement Notice will control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><U>Sale of Placement Shares by the Agent</U>. Subject to the provisions of <U>Section&nbsp;5(a)</U>, the
Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading
and sales practices and applicable state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of the Nasdaq Capital Market
(the &#8220;<B><U>Exchange</U></B>&#8221;), to sell the Placement Shares up to the amount specified in, and otherwise in accordance with
the terms of, such Placement Notice. The Agent will provide written confirmation to the Company no later than the opening of the Trading
Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the
number of Placement Shares sold on such day, the compensation payable by the Company to the Agent pursuant to <U>Section&nbsp;2</U> with
respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the
Agent (as set forth in <U>Section&nbsp;5(b)</U>) from the gross proceeds that it receives from such sales. Subject to the terms of the
Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221;
as defined in Rule&nbsp;415(a)(4)&nbsp;of the Securities Act Regulations, including sales made directly on or through the Exchange or
any other existing trading market for the Common Stock, in negotiated transactions at market prices prevailing at the time of sale or
at prices related to such prevailing market prices. Subject to the terms of the Placement Notice, the Agent may also sell Placement Shares
by any other method permitted by law with the prior written consent of the Company. &#8220;<B><U>Trading Day</U></B>&#8221; means any
day on which Common Stock is traded on the Exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Suspension of Sales</U>. The Company or the Agent may, upon notice to the other party in writing (including
by email correspondence to each of the individuals of the other party set forth on <U>Schedule 3</U>, if receipt of such correspondence
is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately
by verifiable facsimile transmission or email correspondence to each of the individuals of the other party set forth on <U>Schedule 3</U>),
suspend any sale of Placement Shares (a &#8220;<B><U>Suspension</U></B>&#8221;); <I>provided</I>, <I>however</I>, that such Suspension
shall not affect or impair any party&#8217;s obligations with respect
to any Placement Shares sold hereunder prior to the receipt of such notice. While a Suspension is in effect, any obligation under <U>Sections
7(l)</U>, <U>7(m)</U>, <U>7(n)</U>, and <U>7(t)</U>&nbsp;with respect to the delivery of certificates, opinions, or comfort letters to
the Agent shall be waived. Each of the parties agrees that no such notice under this <U>Section&nbsp;4</U> shall be effective against
any other party unless it is made to one of the individuals named on <U>Schedule 3</U> hereto, as such Schedule may be amended from time
to time. Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material non-public
information, the Company and the Agent agree that (i)&nbsp;no sale of Placement Shares will take place, (ii)&nbsp;the Company shall not
request the sale of any Placement Shares, and (iii)&nbsp;the Agent shall not be obligated to sell or offer to sell any Placement Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><U>Sale and Delivery to the Agent; Settlement</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><U>Sale of Placement Shares</U><I>. </I> On the basis of the representations and warranties herein contained
and subject to the terms and conditions herein set forth, upon the Agent&#8217;s acceptance of the terms of a Placement Notice, and unless
the sale of the Placement Shares described therein has been declined, suspended or otherwise terminated in accordance with the terms of
this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with
its normal trading and sales practices and applicable laws, rules&nbsp;and regulations to sell, such Placement Shares up to the amount
specified in, and otherwise in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that (i)&nbsp;there
can be no assurance that the Agent will be successful in selling Placement Shares, (ii)&nbsp;the Agent will incur no liability or obligation
to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent to
use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable laws, rules&nbsp;and regulations
to sell such Placement Shares as required under this Agreement and (iii)&nbsp;the Agent shall be under no obligation to purchase Placement
Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by the Agent and the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Settlement of Placement Shares</U><I>. </I> Unless otherwise specified in the applicable Placement
Notice, settlement for sales of Placement Shares will occur on the second (2<SUP>nd</SUP>) Trading Day (or such earlier day as is industry
practice for regular-way trading) following the date on which such sales are made (each, a &#8220;<B><U>Settlement Date</U></B>&#8221;).
The Agent shall notify the Company of each sale of Placement Shares no later than the opening of the Trading Day immediately following
the Trading Day on which it has made sales of Placement Shares hereunder. The amount of proceeds to be delivered to the Company on a Settlement
Date against receipt of the Placement Shares sold (the &#8220;<B><U>Net Proceeds</U></B>&#8221;) will be equal to the aggregate sales
price received by the Agent, after deduction for (i)&nbsp;the Agent&#8217;s commission, discount or other compensation for such sales
payable by the Company pursuant to <U>Section&nbsp;2</U> hereof, and (ii)&nbsp;any transaction fees imposed by any Governmental Authority
in respect of such sales.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Delivery of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause
its transfer agent to, electronically transfer the Placement Shares being sold by crediting the Agent&#8217;s or its designee&#8217;s
account (provided the Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement
Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System, or by such other means of delivery as may
be mutually agreed upon by the parties hereto, which in all cases shall be freely tradable, transferable, registered shares in good deliverable
form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company
on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation
to deliver Placement Shares on a Settlement Date, through no fault of the Agent, the Company agrees that, in addition to and in no way
limiting the rights and obligations set forth in <U>Section&nbsp;10(a)</U>&nbsp;hereto, it will (i)&nbsp;hold the Agent harmless against
any loss, claim, damage, or reasonable and documented expense (including reasonable and documented legal fees and expenses), as incurred,
arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (ii)&nbsp;pay to the Agent
any commission, discount, or other compensation to which it would otherwise have been entitled absent such default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Denominations; Registration</U><I>. </I>Certificates for the Placement Shares, if any, shall be in
such denominations and registered in such names as the Agent may request in writing at least one full Business Day before the Settlement
Date. The certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Agent
in The City of New York not later than&nbsp;noon (New York time) on the Business Day prior to the Settlement Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Limitations on Offering Size</U><I>. </I>Under no circumstances shall the Company cause or
                                                            request the offer or sale of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross
                                                            sales proceeds of Placement Shares sold pursuant
to this Agreement would exceed the lesser of (A)&nbsp;together with all sales of Placement Shares under this Agreement, the Maximum Amount
and (B)&nbsp;the amount authorized from time to time to be issued and sold under this Agreement by the Company&#8217;s board of directors,
a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances
shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum
price authorized from time to time by the Company&#8217;s board of directors, a duly authorized committee thereof or a duly authorized
executive committee. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares
sold pursuant to this Agreement to exceed the Maximum Amount.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><U>Representations and Warranties of the Company</U>. The Company represents and warrants to, and agrees
with the Agent that as of the date of this Agreement and as of each Applicable Time (as defined below), unless such representation, warranty
or agreement specifies a different time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Registration Statement and Prospectus</U>. The Company and the transactions contemplated by this Agreement
meet the requirements for and comply with the applicable conditions set forth in Form&nbsp;S-3 (including General Instructions I.A and
I.B) under the Securities Act. The Registration Statement has been filed with the Commission and has been declared effective by the Commission
under the Securities Act. The Prospectus Supplement will name the Agent as the agent in the section entitled &#8220;Plan of Distribution.&#8221;
The Company has not received, and has no notice of, any order of the Commission preventing or suspending the use of the Registration Statement,
or threatening or instituting proceedings for that purpose. The Registration Statement and the offer and sale of Placement Shares as contemplated
hereby meet the requirements of Rule&nbsp;415 under the Securities Act and comply in all material respects with said Rule. Any statutes,
regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed
as exhibits to the Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus, and any
such amendments or supplements and all documents incorporated by reference therein that were filed with the Commission on or prior to
the date of this Agreement have been delivered, or are available through EDGAR, to the Agent and its counsel. The Company has not distributed
and, prior to the later to occur of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute
any offering material in connection with the offering or sale of the Placement Shares other than the Registration Statement, the Prospectus
and any Issuer Free Writing Prospectus to which the Agent has consented, such consent not to be unreasonably withheld, conditioned or
delayed. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act and is currently listed on the Exchange
under the trading symbol &#8220;RMTI.&#8221; The Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act, delisting the Common Stock from the Exchange, nor has the Company received
any notification that the Commission or the Exchange is contemplating terminating such registration or listing. Other than as disclosed
in the Registration Statement or the Prospectus, it is in compliance with all applicable listing requirements of the Exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>No Misstatement or Omission</U>. The Registration Statement, when it became or becomes effective, and
the Prospectus, and any amendment or supplement thereto, on the date of such Prospectus or amendment or supplement thereto, conformed
and will conform in all material respects with the requirements of the Securities Act. At each Settlement Date, the Registration Statement
and the Prospectus, as of such date, will conform in all material respects with the requirements of the Securities Act. The Registration
Statement, as of the date it became or becomes effective, did not, and will not, contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus and
any amendment and supplement thereto, on the date thereof and at each Applicable Time (as defined below), did not or will not include
an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. The documents incorporated by reference in the Prospectus or any Prospectus Supplement, as
of their respective dates, did not, and any further documents filed and incorporated by reference therein will not, when filed with the
Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or
necessary to make the statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing
shall not apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished
to the Company by Agent specifically for use in the preparation thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Conformity with Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus or
any amendment or supplement thereto, any Issuer Free Writing Prospectus and the documents incorporated by reference in the Registration
Statement, the Prospectus or any amendment or supplement thereto, when such documents were or are filed with the Commission under the
Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or will conform
in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Financial Information</U>. The consolidated financial statements of the Company included or incorporated
by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, together with the related
notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries
(as defined below) as of the dates indicated and the consolidated results of operations, cash flows and changes in shareholders&#8217;
equity of the Company for the periods specified and have been prepared in compliance with the requirements of the Securities Act and the
Exchange Act and in conformity with GAAP (as defined below) applied on a consistent basis during the periods involved (subject, in the
case of quarterly financial statements, to normal, recurring year-end adjustments); the other financial and statistical data with respect
to the Company and the Subsidiaries (as defined below) contained or incorporated by reference in the Registration Statement, the Prospectus
and the Issuer Free Writing Prospectuses, if any, are accurately and fairly presented, in all material respects, and prepared on a basis
consistent with the financial statements and books and records of the Company; and there are no financial statements (historical or pro
forma) that are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included
or incorporated by reference as required; the Company and the Subsidiaries (as defined below) do not have any material liabilities or
obligations, direct or contingent (including any off-balance sheet obligations), not described in the Registration Statement (including
the incorporated documents but excluding the exhibits thereto) and the Prospectus, to the extent that such disclosure is required by the
Securities Act. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with
the Commission&#8217;s rules&nbsp;and guidelines applicable thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Conformity with EDGAR Filing</U>. The Prospectus delivered to Agent for use in connection with the
sale of the Placement Shares pursuant to this Agreement will be identical to the versions of the Prospectus created to be transmitted
to the Commission for filing via EDGAR, except to the extent permitted by Regulation S&#45;T.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Organization</U>. The Company and each of its Subsidiaries are duly organized, validly existing as
a corporation or other business entity, as the case may be, and in good standing under the laws of their respective jurisdictions of organization.
The Company and each of its Subsidiaries are duly licensed or qualified as a foreign corporation or other business entity, as the case
may be, for transaction of business and in good standing under the laws of each other jurisdiction in which their respective ownership
or lease of property or the conduct of their respective businesses requires such license or qualification, and have all corporate or other
organizational power and authority necessary to own or hold their respective properties and to conduct their respective businesses as
described in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such
power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have
a material adverse effect on or affect the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects,
stockholders&#8217; equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere
with consummation of the transactions contemplated hereby (a &#8220;<B><U>Material Adverse Effect</U></B>&#8221;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Subsidiaries</U>. The subsidiaries set forth on <U>Schedule 4</U> (collectively, the &#8220;<B><U>Subsidiaries</U></B>&#8221;),
are the Company&#8217;s only significant subsidiaries (as such term is defined in Rule&nbsp;1&#45;02 of Regulation S&#45;X promulgated
by the Commission). Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly,
all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal
or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of
preemptive and similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such Subsidiary&#8217;s capital stock, from repaying to the Company any loans or advances to such
Subsidiary from the Company or from transferring any of such Subsidiary&#8217;s property or assets to the Company or any other Subsidiary
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify"><U>No Violation or Default</U>. Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation
of its charter or by&#45;laws or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or
lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained
in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries
is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any
of its Subsidiaries are subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule&nbsp;or regulation of any
Governmental Authority, except, in the case of each of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such violation or default that
would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&#8217;s knowledge, no other party under any
material contract or other agreement to which it or any of its Subsidiaries is a party is in default in any respect thereunder where such
default would have a Material Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><U>No Material Adverse Change</U>. Subsequent to the respective dates as of which information is given
in the Registration Statement, the Prospectus and the Free Writing Prospectuses, if any (including any document deemed incorporated by
reference therein), there has not been (i)&nbsp;any Material Adverse Effect or the occurrence of any development that the Company reasonably
expects will result in a Material Adverse Effect, (ii)&nbsp;any transaction which is material to the Company and the Subsidiaries taken
as a whole, (iii)&nbsp;any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the
Company or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv)&nbsp;any material change in the
capital stock or outstanding long-term indebtedness of the Company or any of its Subsidiaries or (v)&nbsp;any dividend or distribution
of any kind declared, paid or made on the capital stock of the Company or any Subsidiary, other than in each case above in the ordinary
course of business or as otherwise disclosed in the Registration Statement or Prospectus (including any document deemed incorporated by
reference therein).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><U>Capitalization</U>. The issued and outstanding shares of capital stock of the Company have been validly
issued, are fully paid and nonassessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject
to any preemptive rights, rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization
as set forth in the Registration Statement and the Prospectus as of the dates referred to therein (other than the grant of additional
options under the Company&#8217;s existing stock option plans, or changes in the number of outstanding shares of Common Stock of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding
on the date hereof) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement and
the Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus is complete and accurate
in all material respects. Except as disclosed in or contemplated by the Registration Statement or the Prospectus, as of the date referred
to therein, the Company does not have outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities
or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or
other securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify"><U>Authorization; Enforceability</U>. The Company has full legal right, power and authority to enter into
this Agreement and perform the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the
Company and is a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights
generally and by general equitable principles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify"><U>Authorization of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to
the terms approved by the board of directors of the Company or a duly authorized committee thereof, or a duly authorized executive committee,
against payment therefor as provided herein, will be duly and validly authorized and issued and fully paid and nonassessable, free and
clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory or contractual preemptive rights, resale
rights, rights of first refusal or other similar rights, and will be registered pursuant to Section&nbsp;12 of the Exchange Act. The Placement
Shares, when issued, will conform to the description thereof set forth in or incorporated into the Prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(m)</TD><TD STYLE="text-align: justify"><U>No Consents Required</U>. No consent, approval, authorization, order, registration or qualification
of or with any Governmental Authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance
and sale by the Company of the Placement Shares, except for such consents, approvals, authorizations, orders and registrations or qualifications
as may be required under applicable state securities laws or by the by&#45;laws and rules&nbsp;of the Financial Industry Regulatory Authority
(&#8220;<B><U>FINRA</U></B>&#8221;) or the Exchange in connection with the sale of the Placement Shares by the Agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(n)</TD><TD STYLE="text-align: justify"><U>No Preferential Rights</U>. Except as set forth in the Registration Statement and the Prospectus, (i)&nbsp;no
person, as such term is defined in Rule&nbsp;1&#45;02 of Regulation S&#45;X promulgated under the Securities Act (each, a &#8220;<B><U>Person</U></B>&#8221;),
has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other
capital stock or other securities of the Company, (ii)&nbsp;no Person has any preemptive rights, resale rights, rights of first refusal,
rights of co-sale, or any other rights (whether pursuant to a &#8220;poison pill&#8221; provision or otherwise) to purchase any Common
Stock or shares of any other capital stock or other securities of the Company, (iii)&nbsp;no Person has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Placement Shares, and (iv)&nbsp;no Person has the
right, contractual or otherwise, to require the Company to register under the Securities Act any Common Stock or shares of any other capital
stock or other securities of the Company, or to include any such shares or other securities in the Registration Statement
or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of
the Placement Shares as contemplated thereby or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(o)</TD><TD STYLE="text-align: justify"><U>Independent Public Accounting Firm</U>. Marcum LLP (the &#8220;<B><U>Accountant</U></B>&#8221;), whose
report on the consolidated financial statements of the Company is filed with the Commission as part of the Company&#8217;s most recent
Annual Report on Form&nbsp;10-K filed with the Commission and incorporated by reference into the Registration Statement and the Prospectus,
is and, during the periods covered by its report, was an independent registered public accounting firm within the meaning of the Securities
Act and the Public Company Accounting Oversight Board (United States). To the Company&#8217;s knowledge, the Accountant is not in violation
of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &#8220;<B><U>Sarbanes-Oxley Act</U></B>&#8221;) with respect
to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(p)</TD><TD STYLE="text-align: justify"><U>Enforceability of Agreements</U>. All agreements between the Company and third parties expressly referenced
in the Prospectus are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except
to the extent that (i)&nbsp;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors&#8217; rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements
may be limited by federal or state securities laws or public policy considerations in respect thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(q)</TD><TD STYLE="text-align: justify"><U>No Litigation</U>. Except as set forth in the Registration Statement or the Prospectus, there are no
actions, suits or proceedings by or before any Governmental Authority pending, nor, to the Company&#8217;s knowledge, any audits or investigations
by or before any Governmental Authority, to which the Company or a Subsidiary is a party or to which any property of the Company or any
of its Subsidiaries is the subject that, individually or in the aggregate, if determined adversely to the Company or a Subsidiary, would
have a Material Adverse Effect and, to the Company&#8217;s knowledge, no such actions, suits, proceedings, audits or investigations are
threatened or contemplated by any Governmental Authority or threatened by others; and (i)&nbsp;there are no current or pending audits,
investigations, actions, suits or proceedings by or before any Governmental Authority that are required under the Securities Act to be
described in the Prospectus that are not so described; and (ii)&nbsp;there are no contracts or other documents that are required under
the Securities Act to be filed as exhibits to the Registration Statement that are not so filed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(r)</TD><TD STYLE="text-align: justify"><U>Consents and Permits</U>. Except as disclosed in the Registration Statement and the Prospectus, the
Company and its Subsidiaries have made all filings, applications and submissions required by, possesses and is operating in compliance
with, all approvals, licenses, certificates, certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits
and other authorizations issued by, the appropriate federal, state or foreign Governmental Authority (including, without limitation, the
United States Food and Drug Administration (the &#8220;<B><U>FDA</U></B>&#8221;), the United States Drug Enforcement Administration or
any other foreign, federal, state, provincial, court or local government or regulatory authorities including self-regulatory organizations
engaged in the regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or materials) necessary for the ownership
or lease of their respective properties or to conduct its businesses as described in the Registration Statement and the Prospectus (collectively,
 &#8220;<B><U>Permits</U></B>&#8221;), except for such Permits the failure of which to possess, obtain or make the same would not have
a Material Adverse Effect; the Company and its Subsidiaries are in compliance with the terms and conditions of all such Permits, except
where the failure to be in compliance would not have a Material Adverse Effect; all of the Permits are valid and in full force and effect,
except where any invalidity, individually or in the aggregate, would not be reasonably expected to have a Material Adverse Effect; and
neither the Company nor any of its Subsidiaries has received any written notice relating to the limitation, revocation, cancellation,
suspension, modification or non-renewal of any such Permit which, singly or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would have a Material Adverse Effect, or has any reason to believe that any such license, certificate, permit or authorization
will not be renewed in the ordinary course. To the extent required by applicable laws and regulations of the FDA, the Company or the applicable
Subsidiary has submitted to the FDA an Investigational New Drug Application or amendment or supplement thereto for each clinical trial
it has conducted or sponsored or is conducting or sponsoring; all such submissions were in material compliance with applicable laws and
rules&nbsp;and regulations when submitted and no material deficiencies have been asserted by the FDA with respect to any such submissions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(s)</TD><TD STYLE="text-align: justify"><U>Regulatory Filings</U>. Except as disclosed in the Registration Statement and the Prospectus, neither
the Company nor any of its Subsidiaries has failed to file with the applicable Governmental Authorities (including, without limitation,
the FDA, or any foreign, federal, state, provincial or local Governmental Authority performing functions similar to those performed by
the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or
in the aggregate, would not have a Material Adverse Effect;
except as disclosed in the Registration Statement and the Prospectus, all such filings, declarations, listings, registrations, reports
or submissions were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory
authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies
that, individually or in the aggregate, would not have a Material Adverse Effect. The Company has operated and currently is, in all material
respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules&nbsp;and regulations of the
FDA and other federal, state, local and foreign Governmental Authority exercising comparable authority. The Company has no knowledge of
any studies, tests or trials not described in the Prospectus the results of which reasonably call into question in any material respect
the results of the studies, tests and trials described in the Prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(t)</TD><TD STYLE="text-align: justify"><U>Intellectual Property</U>. Except as disclosed in the Registration Statement and the Prospectus, the
Company and its Subsidiaries own, possess, license or have other rights to use all foreign and domestic patents, patent applications,
trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology,&nbsp;Internet
domain names, know-how and other intellectual property (collectively, the &#8220;<B><U>Intellectual Property</U></B>&#8221;), necessary
for the conduct of their respective businesses as now conducted except to the extent that the failure to own, possess, license or otherwise
hold adequate rights to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except
as disclosed in the Registration Statement and the Prospectus (i)&nbsp;there are no rights of third parties to any such Intellectual Property
owned by the Company and its Subsidiaries; (ii)&nbsp;to the Company&#8217;s knowledge, there is no infringement by third parties of any
such Intellectual Property; (iii)&nbsp;there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or
claim by others challenging the Company&#8217;s and its Subsidiaries&#8217; rights in or to any such Intellectual Property, and the Company
is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv)&nbsp;there is no pending
or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any
such Intellectual Property; (v)&nbsp;there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or
claim by others that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright, trade secret or
other proprietary rights of others; (vi)&nbsp;to the Company&#8217;s knowledge, there is no third-party U.S. patent or published U.S.
patent application which contains claims for which an Interference Proceeding (as defined in 35 U.S.C. &sect; 135) has been commenced
against any patent or patent application described in the Prospectus as being owned by or licensed to the Company; and (vii)&nbsp;the
Company and its Subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property
has been licensed to the Company or such Subsidiary, and all such agreements are in full force and effect, except, in the case of any
of clauses (i)-(vii)&nbsp;above, for any such infringement by third parties or any such pending or threatened suit, action, proceeding
or claim as would not, individually or in the aggregate, result in a Material Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(u)</TD><TD STYLE="text-align: justify"><U>Clinical Studies</U>. The preclinical studies and tests and clinical trials described in the Prospectus
were, and, if still pending, are being conducted in all material respects in accordance with the experimental protocols, procedures and
controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to
those being developed by the Company; the descriptions of such studies, tests and trials, and the results thereof, contained in the Prospectus
are accurate and complete in all material respects; the Company is not aware of any tests, studies or trials not described in the Prospectus,
the results of which reasonably call into question the results of the tests, studies and trials described in the Prospectus; and the Company
has not received any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority exercising comparable
authority or any institutional review board or comparable authority requiring the termination, suspension, clinical hold or material modification
of any tests, studies or trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify"><U>Market Capitalization</U>. At the time the Registration Statement was originally declared effective,
and at the time the Company&#8217;s most recent Annual Report on Form&nbsp;10-K was filed with the Commission, the Company met the then
applicable requirements for the use of Form&nbsp;S-3 under the Securities Act, including, but not limited to, General Instruction I.B.6
of Form&nbsp;S-3. The aggregate market value&nbsp;of the outstanding voting and non-voting common equity (as defined in Securities Act
Rule&nbsp;405) of the Company held by persons other than affiliates of the Company (pursuant to Securities Act Rule&nbsp;144, those that
directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company)&nbsp;
(the &#8220;<B><U>Non-Affiliate Shares</U></B>&#8221;), was equal to $36,746,492 (calculated by multiplying (x)&nbsp;the highest price
at which the common equity of the Company closed on the Exchange within 60 days of the date of this Agreement times (y)&nbsp;the number
of Non-Affiliate Shares). The Company is not a shell company (as defined in Rule&nbsp;405 under the Securities Act) and has not been a
shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current
Form&nbsp;10 information (as defined in Instruction I.B.6 of Form&nbsp;S-3) with the Commission at least 12 calendar months previously
reflecting its status as an entity that is not a shell company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(w)</TD><TD STYLE="text-align: justify"><U>No Material Defaults</U>. Neither the Company nor any of the Subsidiaries has defaulted on any installment
on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate,
would have a Material Adverse Effect. The Company has not filed a report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange
Act since the filing of its last Annual Report on Form&nbsp;10&#45;K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking
fund installment on preferred stock or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental
on one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(x)</TD><TD STYLE="text-align: justify"><U>Certain Market Activities</U>. Neither the Company, nor any of the Subsidiaries, nor any of their respective
directors, officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably
be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security
of the Company to facilitate the sale or resale of the Placement Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(y)</TD><TD STYLE="text-align: justify"><U>Broker/Dealer Relationships</U>. Neither the Company nor any of the Subsidiaries (i)&nbsp;is required
to register with the Commission as a &#8220;broker&#8221; or &#8220;dealer&#8221; in accordance with the provisions of the Exchange Act
or (ii)&nbsp;directly or indirectly through one or more intermediaries, controls or is a &#8220;person associated with a member&#8221;
or &#8220;associated person of a member&#8221; (within the meaning set forth in the FINRA Manual).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(z)</TD><TD STYLE="text-align: justify"><U>No Reliance</U>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal,
tax or accounting advice in connection with the offering and sale of the Placement Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(aa)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
                                            The Company and each of its Subsidiaries have filed all federal, state, local and foreign
                                            tax returns which have been required to be filed and paid all taxes shown thereon through
                                            the date hereof, to the extent that such taxes have become due and are not being contested
                                            in good faith, except where the failure to so file or pay would not have a Material Adverse
                                            Effect. Except as otherwise disclosed in or contemplated by the Registration Statement or
                                            the Prospectus, no tax deficiency has been determined adversely to the Company or any of
                                            its Subsidiaries which has had, or would have, individually or in the aggregate, a Material
                                            Adverse Effect. The Company has no knowledge of any federal, state or other governmental
                                            tax deficiency, penalty or assessment which has been or might be asserted or threatened against
                                            it which would have a Material Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(bb)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
                                            to Real and Personal Property</U>. The Company owns no real property and the Company and
                                            its Subsidiaries have valid rights to lease or to use all items of real or personal property
                                            that are material to the business of the Company and its Subsidiaries, in each case free
                                            and clear of all liens, encumbrances and claims, except those matters that (i)&nbsp;do not
                                            materially interfere with the use made and proposed to be made of such property by the Company
                                            and any of its Subsidiaries or (ii)&nbsp;would not, individually or in the aggregate, have
                                            a Material Adverse Effect. Any real or personal property described in the Registration Statement
                                            or Prospectus as being leased by the Company and any of its Subsidiaries is held by them
                                            under valid, existing and enforceable leases, except those that (A)&nbsp;do not materially
                                            interfere with the use made or proposed to be made of such property by the Company or any
                                            of its Subsidiaries or (B)&nbsp;would not be reasonably expected, individually or in the
                                            aggregate, to have a Material Adverse Effect. Each of the properties of the Company and its
                                            Subsidiaries complies with all applicable codes, laws and regulations (including, without
                                            limitation, building and zoning codes, laws and regulations and laws relating to access to
                                            such properties), except if and to the extent disclosed in the Registration Statement or
                                            Prospectus or except for such failures to comply that would not, individually or in the aggregate,
                                            reasonably be expected to have a Material Adverse Effect. None of the Company or its subsidiaries
                                            has received from any Governmental Authorities any notice of any condemnation of, or zoning
                                            change affecting, the properties of the Company and its Subsidiaries, and the Company knows
                                            of no such condemnation or zoning change which is threatened, except for such that would
                                            not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(cc)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
                                            Laws.</U> Except as set forth in the Registration Statement or the Prospectus, the Company
                                            and its Subsidiaries (i)&nbsp;are in compliance with any and all applicable federal, state,
                                            local and foreign laws, rules, regulations, decisions and orders relating to the protection
                                            of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
                                            or contaminants (collectively, &#8220;<B>Environmental Laws</B>&#8221;); (ii)&nbsp;have received
                                            and are in compliance with all permits, licenses or other approvals required of them under
                                            applicable Environmental Laws to conduct their respective businesses as described in the
                                            Registration Statement and the Prospectus; and (iii)&nbsp;have not received notice of any
                                            actual or potential liability for the investigation or remediation of any disposal or release
                                            of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case
                                            of any of clauses (i), (ii)&nbsp;or (iii)&nbsp;above, for any such failure to comply or failure
                                            to receive required permits, licenses, other approvals or liability as would not, individually
                                            or in the aggregate, have a Material Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(dd)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure Controls</U>. The Company and each of its Subsidiaries maintain systems of internal accounting
controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#8217;s general
or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance
with management&#8217;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company&#8217;s internal control over
financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting
(other than as set forth in the Prospectus). Since the date of the latest audited financial statements of the Company included in the
Prospectus, there has been no change in the Company&#8217;s internal control over financial reporting that has materially and adversely
affected, or is reasonably likely to materially and adversely affect, the Company&#8217;s internal control over financial reporting (other
than as set forth in the Prospectus). The Company has established disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a&#45;15
and 15d&#45;15) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the
Company and each of its Subsidiaries is made known to the certifying officers by others within those entities, particularly during the
period in which the Company&#8217;s Annual Report on Form&nbsp;10&#45;K or Quarterly Report on Form&nbsp;10-Q, as the case may be, is
being prepared. The Company&#8217;s certifying officers have evaluated the effectiveness of the Company&#8217;s disclosure controls and
procedures as of a date within 90 days prior to the filing date of the Form&nbsp;10&#45;K for the fiscal year most recently ended (such
date, the <B>&#8220;<U>Evaluation Date</U></B>&#8221;). The Company presented in its Form&nbsp;10&#45;K for the fiscal year most recently
ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date and, except as set forth in the registration Statement and Prospectus, the disclosure controls and procedures
are effective. Since the Evaluation Date, there have been no significant changes in the Company&#8217;s internal controls (as such term
is defined in Item 307(b)&nbsp;of Regulation S&#45;K under the Securities Act) or, to the Company&#8217;s knowledge, in other factors
that could significantly affect the Company&#8217;s internal controls.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(ee)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley</U>. There is and has been no failure on the part of the Company or any of the Company&#8217;s
directors or officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley
Act and the rules&nbsp;and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer
of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as
applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules,
forms, statements and other documents required to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence,
 &#8220;principal executive officer&#8221; and &#8220;principal financial officer&#8221; shall have the meanings given to such terms in
the Sarbanes-Oxley Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(ff)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Finder&#8217;s Fees</U>. Neither the Company nor any of the Subsidiaries has incurred any liability
for any finder&#8217;s fees, brokerage commissions or similar payments in connection with the transactions herein contemplated, except
as may otherwise exist with respect to the Agent pursuant to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(gg)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Disputes</U>. No labor disturbance by or dispute with employees of the Company or any of its Subsidiaries exists or, to the knowledge
of the Company, is threatened which would result in a Material Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(hh)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment Company Act</U>. Neither the Company nor any of the Subsidiaries is or, after giving effect
to the offering and sale of the Placement Shares, will be an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by
an &#8220;investment company,&#8221; as such terms are defined in the Investment Company Act of 1940, as amended (the &#8220;<B><U>Investment
Company Act</U></B>&#8221;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Operations</U>. The operations of the Company and its Subsidiaries are and have been conducted at all
times in compliance with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the
rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by
any Governmental Authority (collectively, the &#8220;<B><U>Money Laundering Laws</U></B>&#8221;); and no action, suit or proceeding by
or before any Governmental Authority involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending
or, to the knowledge of the Company, threatened.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(jj)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Off-Balance Sheet Arrangements</U>. There are no transactions, arrangements and other relationships
between and/or among the Company and/or any of its affiliates and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity (each, an &#8220;<B><U>Off-Balance Sheet Transaction</U></B>&#8221;) that could reasonably
be expected to affect materially the Company&#8217;s liquidity or the availability of or requirements for
its capital resources, including those Off-Balance Sheet Transactions described in the Commission&#8217;s Statement about Management&#8217;s
Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33&#45;8056; 34&#45;45321; FR&#45;61), required
to be described in the Prospectus which have not been described as required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(kk)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter Agreements</U>. The Company is not a party to any agreement with an agent or underwriter
for any other &#8220;at the market&#8221; or continuous equity transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ll)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ERISA</U>.
To the knowledge of the Company, each material employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement
Income Security Act of 1974, as amended (&#8220;<B><U>ERISA</U></B>&#8221;), that is maintained, administered or contributed to by the
Company or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in
material compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but
not limited to ERISA and the Internal Revenue Code of 1986, as amended (the &#8220;<B><U>Code</U></B>&#8221;); no prohibited transaction,
within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred which would result in a material liability
to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and
for each such plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no &#8220;accumulated
funding deficiency&#8221; as defined in Section&nbsp;412 of the Code has been incurred, whether or not waived, and the fair market value
of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits
accrued under such plan determined using reasonable actuarial assumptions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(mm)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section&nbsp;27A
of the Securities Act and Section&nbsp;21E of the Exchange Act) (a &#8220;<B><U>Forward-Looking Statement</U></B>&#8221;) contained in
the Registration Statement and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than
in good faith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(nn)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agent Purchases</U>. The Company acknowledges and agrees that Agent has informed the Company that the
Agent may, to the extent permitted under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while
this Agreement is in effect, <I>provided</I>, that&nbsp;the Company shall not be deemed to have authorized or consented to any such purchases
or sales by the Agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.27in">(oo)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Margin Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application
of the proceeds thereof by the Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X
of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(pp)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Company and each of its Subsidiaries carry, or are covered by, insurance in such
amounts and covering such risks as the Company and each of its Subsidiaries reasonably believe are adequate for the conduct of their properties
and as is customary for companies engaged in similar businesses in similar industries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(qq)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Improper Practices</U>. (i)&nbsp;Neither the Company nor the Subsidiaries, nor to the Company&#8217;s knowledge, any director, officer
or employee of the Company or any agent, affiliate, or other person acting on behalf of the Company or any Subsidiary has, in the past
five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in
violation of applicable law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal,
or foreign office or other person charged with similar public or quasi-public duty in violation of any applicable law or of the character
required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct or indirect, exists between or among the Company or any
Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of the Company or any Subsidiary,
on the other hand, that is required by the Securities Act to be described in the Registration Statement and the Prospectus that is not
so described; (iii)&nbsp;no relationship, direct or indirect, exists between or among the Company or any Subsidiary or any affiliate
of them, on the one hand, and the directors, officers, or stockholders of the Company or any Subsidiary, on the other hand, that is required
by the rules&nbsp;of FINRA to be described in the Registration Statement and the Prospectus that is not so described; (iv)&nbsp;except
as described in the Registration Statement and the Prospectus, there are no material outstanding loans or advances or material guarantees
of indebtedness by the Company or any Subsidiary to or for the benefit of any of their respective officers or directors or any of the
members of the families of any of them; (v)&nbsp;the Company has not offered, or caused any placement agent to offer, Common Stock to
any person with the intent to influence unlawfully (A)&nbsp;a customer or supplier of the Company or any Subsidiary to alter the customer&#8217;s
or supplier&#8217;s level or type of business with the Company or any Subsidiary or (B)&nbsp;a trade journalist or publication to write
or publish favorable information about the Company or any Subsidiary or any of their respective products or services; and (vi)&nbsp;neither
the Company nor any Subsidiary nor any director, officer, or employee of the Company or any Subsidiary nor, to the Company&#8217;s knowledge,
any agent, affiliate, or other person acting on behalf of the Company or any Subsidiary has (A)&nbsp;violated or is in violation of any
applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery or anti-corruption
law (collectively, &#8220;<B><U>Anti-Corruption Laws</U></B>&#8221;), (B)&nbsp;promised, offered, provided, attempted to provide, or
authorized the provision of anything of value, directly or indirectly, to any person for the purpose of obtaining or retaining business,
influencing any act or decision of the recipient, or securing any improper advantage; or (C)&nbsp;made any payment of funds of the Company
or any Subsidiary or received or retained any funds in violation of any Anti-Corruption Laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(rr)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Status
Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule&nbsp;405 under the Securities Act
at the times specified in Rules&nbsp;164 and 433 under the Securities Act in connection with the offering of the Placement Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ss)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, if any, as of its issue date
and as of each Applicable Time (as defined in <U>Section&nbsp;23 </U>below), did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any
incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to
statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to
the Company by the Agent specifically for use therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(tt)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation
of any of the transactions contemplated herein, nor the compliance by the Company with the terms and provisions hereof will conflict
with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under, or has
resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the property or assets
of the Company is subject, except (i)&nbsp;such conflicts, breaches or defaults as may have been waived and (ii)&nbsp;such conflicts,
breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x)&nbsp;in any violation of the provisions
of the organizational or governing documents of the Company, or (y)&nbsp;in any material violation of the provisions of any statute or
any order, rule&nbsp;or regulation applicable to the Company or of any Governmental Authority having jurisdiction over the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(uu)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sanctions</U>.
                                            (i)&nbsp;The Company represents that, neither the Company nor any of its Subsidiaries (collectively,
                                            the &#8220;<B><U>Entity</U></B>&#8221;) or, to the knowledge of the Company, any director,
                                            officer, employee, agent, affiliate or representative of the Entity, is a government, individual,
                                            or entity (in this paragraph (uu), &#8220;<B><U>Person</U></B>&#8221;) that is, or is owned
                                            or controlled by a Person that is:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.5in">(A)&nbsp;&nbsp;the
subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control (&#8220;<B><U>OFAC</U></B>&#8221;),
the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury, or other relevant sanctions authorities, including,
without limitation, designation on OFAC&#8217;s Specially Designated Nationals and Blocked Persons List or OFAC&#8217;s Foreign Sanctions
Evaders List (as amended, collectively, &#8220;<B><U>Sanctions</U></B>&#8221;), nor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.5in">(B)&nbsp;&nbsp;located,
organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory
(including, without limitation, Cuba, Donetsk People&#8217;s Republic,&nbsp;Iran, Luhansk People&#8217;s Republic, North Korea, Syria,
and the Crimea Region of the Ukraine) (the &#8220;<B><U>Sanctioned Countries</U></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify">(ii)&nbsp;&nbsp;The Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.5in">(A)&nbsp;&nbsp;to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
facilitation, is the subject of Sanctions or is a Sanctioned Country; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.5in">(B)&nbsp;&nbsp;in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify">(iii)&nbsp;&nbsp;The Entity represents and covenants that, except as described in the Registration Statement and the Prospectus, for
the past 5 years, it has not engaged in, is not now engaging in, and will not engage in, any dealings or transactions with any Person,
or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or is or was a Sanctioned
Country.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(vv)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to be paid
in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid or provided
for by the Company and all laws imposing such taxes will be or will have been fully complied with.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ww)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Laws</U>. Each of the Company and its Subsidiaries: (A)&nbsp;is and at all times has been in compliance with all statutes, rules,
or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company or its
Subsidiaries (&#8220;<B><U>Applicable Laws</U></B>&#8221;), except as could not, individually or in the aggregate, reasonably be expected
to result in a Material Adverse Effect; (B)&nbsp;has not received any FDA Form&nbsp;483, notice of adverse finding, warning letter, untitled
letter or other correspondence or notice from the FDA or any other Governmental Authority alleging or asserting noncompliance with any
Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required
by any such Applicable Laws (&#8220;<B><U>Authorizations</U></B>&#8221;); (C)&nbsp;possesses all material Authorizations and such Authorizations
are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (D)&nbsp;has not received
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental
Authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and
has no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; (E)&nbsp;has not received notice that any Governmental Authority has taken, is taking or intends to
take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering
such action; (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed
(or were corrected or supplemented by a subsequent submission); and (G)&nbsp;has not, either voluntarily or involuntarily, initiated,
conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post
sale warning, &#8220;dear healthcare provider&#8221; letter, or other notice or action relating to the alleged lack of safety or efficacy
of any product or any alleged product defect or violation and, to the Company&#8217;s knowledge, no third party has initiated, conducted
or intends to initiate any such notice or action.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(xx)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Statistical
                                            and Market-Related Data</U>.&nbsp; The statistical, demographic and market-related data included
                                            in the Registration Statement and Prospectus are based on or derived from sources that the
                                            Company believes to be reliable and accurate or represent the Company&#8217;s good faith
                                            estimates that are made on the basis of data derived from such sources.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(yy)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cybersecurity</U>.
                                            The Company and its Subsidiaries&#8217; information technology assets and equipment, computers,
                                            systems, networks, hardware, software, websites, applications, and databases (collectively,
                                            &#8220;<B><U>IT Systems</U></B>&#8221;) are adequate for, and operate and perform in all
                                            material respects as required in connection with the operation of the business of the Company
                                            as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses,
                                            time bombs, malware and other corruptants. The Company and its Subsidiaries have implemented
                                            and maintained commercially reasonable physical, technical and administrative controls, policies,
                                            procedures, and safeguards to maintain and protect their material confidential information
                                            and the integrity, continuous operation, redundancy and security of all IT Systems and data,
                                            including all &#8220;Personal Data&#8221; (defined below) and all sensitive, confidential
                                            or regulated data (&#8220;<B><U>Confidential Data</U></B>&#8221;) used in connection with
                                            their businesses. &#8220;<B><U>Personal Data</U></B>&#8221; means (i)&nbsp;a natural person&#8217;s
                                            name, street address, telephone number, e-mail address, photograph, social security number
                                            or tax identification number, driver&#8217;s license number, passport number, credit card
                                            number, bank information, or customer or account number; (ii)&nbsp;any information which
                                            would qualify as &#8220;personally identifying information&#8221; under the Federal Trade
                                            Commission Act, as amended; (iii)&nbsp;&#8220;personal data&#8221; as defined by GDPR (as
                                            defined below); (iv)&nbsp;any information which would qualify as &#8220;protected health
                                            information&#8221; under the Health Insurance Portability and Accountability Act of 1996,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act (collectively,
                                            &#8220;<B><U>HIPAA</U></B>&#8221;); (v)&nbsp;any &#8220;personal information&#8221; as defined
                                            by the California Consumer Privacy Act (&#8220;<B><U>CCPA</U></B>&#8221;); and (vi)&nbsp;any
                                            other piece of information that allows the identification of such natural person, or his
                                            or her family, or permits the collection or analysis of any data related to an identified
                                            person&#8217;s health or sexual orientation. There have been no breaches, violations, outages
                                            or unauthorized uses of or accesses to same, except for those that have been remedied without
                                            material cost or liability or the duty to notify any other person, nor any incidents under
                                            internal review or investigations relating to the same. The Company and its Subsidiaries
                                            are presently in material compliance with all applicable laws or statutes and all judgments,
                                            orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory
                                            authority, internal policies and contractual obligations relating to the privacy and security
                                            of IT Systems, Confidential Data, and Personal Data and to the protection of such IT Systems,
                                            Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(zz)</TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
                                            with Data Privacy Laws</U>. The Company and its Subsidiaries are, and at all prior times
                                            were, in material compliance with all applicable state and federal data privacy and security
                                            laws and regulations, including without limitation HIPAA, CCPA, and the European Union General
                                            Data Protection Regulation (&#8220;<B><U>GDPR</U></B>&#8221;) (EU 2016/679) (collectively,
                                            the &#8220;<B><U>Privacy Laws</U></B>&#8221;). To ensure compliance with the Privacy Laws,
                                            the Company has in place, complies with, and takes appropriate steps to ensure compliance
                                            in all material respects with their policies and procedures relating to data privacy and
                                            security and the collection, storage, use, processing, disclosure, handling, and analysis
                                            of Personal Data and Confidential Data (the &#8220;<B><U>Policies</U></B>&#8221;). The Company
                                            has at all times made all disclosures to users or customers required by applicable laws and
                                            regulatory rules&nbsp;or requirements, and none of such disclosures made or contained in
                                            any Policy have been inaccurate or in violation of any applicable laws and regulatory rules&nbsp;or
                                            requirements in any material respect. The Company further certifies that neither it nor any
                                            subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating
                                            to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of
                                            any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is
                                            currently conducting or paying for, in whole or in part, any investigation, remediation,
                                            or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order,
                                            decree, or agreement that imposes any obligation or liability under any Privacy Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any certificate signed by
an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this Agreement shall
be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><U>Covenants of the Company</U>. The Company covenants and agrees with Agent that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Registration Statement Amendments</U>. After the date of this Agreement and during any period in which
a Prospectus relating to any Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances
where such requirement may be satisfied pursuant to Rule&nbsp;172 under the Securities Act or any similar rule), (i)&nbsp;the Company
will notify the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated
by reference, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed
and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information,
(ii)&nbsp;the Company will prepare and file with the Commission, promptly upon the Agent&#8217;s request, any amendments or supplements
to the Registration Statement or Prospectus that, in the Agent&#8217;s reasonable opinion, based on the advice of counsel, may be necessary
or advisable in connection with the distribution of the Placement Shares by the Agent (<I>provided</I>, <I>however</I>, that the failure
of the Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#8217;s
right to rely on the representations and warranties made by the Company in this Agreement and <I>provided</I>, <I>further</I>, that the
only remedy the Agent shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement until
such amendment or supplement is filed); (iii)&nbsp;the Company will not file any amendment or supplement to the Registration Statement
or Prospectus relating to the Placement Shares (other than documents incorporated by reference) or a security convertible into the Placement
Shares unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and the Agent has not
reasonably objected thereto in writing within two (2)&nbsp;Business Days (<I>provided</I>, <I>however</I>, that the failure of the Agent
to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#8217;s right to rely
on the representations and warranties made by the Company in this Agreement, and the Company has no obligation to provide the Agent any
advance copy of such filing or to provide the Agent an opportunity to object to such filing if such filing does not name the Agent and
does not reference the transactions contemplated hereby; <I>provided</I>, <I>further</I>, that the only remedy the Agent shall have with
respect to the failure by the Company to obtain such consent shall be to cease making sales under this Agreement) and the Company will
furnish to the Agent at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into
the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv)&nbsp;the Company will cause each amendment
or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule&nbsp;424(b)&nbsp;of
the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the Commission as required
pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement with
the Commission under this <U>Section&nbsp;7(a)</U>, based on the Company&#8217;s reasonable opinion or reasonable objections, shall be
made exclusively by the Company).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 224.25pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Notice of Commission Stop Orders</U>. The Company will advise the Agent, promptly after it receives
notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction,
or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts
to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the
Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment or supplements
to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares,
the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Delivery of Prospectus; Subsequent Changes</U>. During any period in which a Prospectus relating to
the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement
Shares, (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172 under the Securities Act or similar
rule), the Company will comply in all material respects with all requirements imposed upon it by the Securities Act, as from time to time
in force, and to file on or before their respective due dates all reports and any definitive proxy or information statements required
to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d)&nbsp;or any other provision of or under the
Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to Rule&nbsp;430B under the Securities
Act, it will use its commercially reasonable efforts to comply with the provisions of and make all requisite filings with the Commission
pursuant to said Rule&nbsp;430B and to notify the Agent promptly of all such filings. If during such period any event occurs as a result
of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period
it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly
notify the Agent to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the
Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance;
<I>provided</I>, <I>however</I>, that the Company may delay any such amendment or supplement, if, in the reasonable judgment of the Company,
it is in the best interests of the Company to do so.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 03 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 97%"><U>Listing of Placement Shares</U>. Prior to the date of the first Placement Notice, the Company will
use its commercially reasonable efforts to cause the Placement Shares to be listed on the Exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(e)</TD><TD STYLE="text-align: justify; width: 97%"><U>Delivery of Registration Statement and Prospectus</U>. The Company will furnish to the Agent and its
counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by
reference therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during
any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all
documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case, as soon
as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent&#8217;s request,
will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; <I>provided</I>,
<I>however</I>, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agent to the extent
such document is available on EDGAR.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(f)</TD><TD STYLE="text-align: justify; width: 97%"><U>Earnings Statement</U>. The Company will make generally available to its security holders as soon as
practicable, but in any event not later than 15 months after the end of the Company&#8217;s current fiscal quarter, an earnings statement
covering a 12-month period that satisfies the provisions of Section&nbsp;11(a)&nbsp;and Rule&nbsp;158 of the Securities Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(g)</TD><TD STYLE="text-align: justify; width: 97%"><U>Use of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section
entitled &#8220;Use of Proceeds.&#8221;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(h)</TD><TD STYLE="text-align: justify; width: 97%"><U>Notice of Other Sales</U>. Without the prior written consent of the Agent, the Company will not, directly
or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the
Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any
rights to purchase or acquire, Common Stock during the period beginning on the third (3<SUP>rd</SUP>) Trading Day immediately prior to
the date on which any Placement Notice is delivered to the Agent hereunder and ending on the third (3<SUP>rd</SUP>) Trading Day immediately
following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice
has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension
or termination); and will not directly or indirectly in any other &#8220;at the market offering&#8221; or continuous equity transaction
offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares
offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase
or acquire, Common Stock prior to the later of the termination of this Agreement and the sixtieth (60<SUP>th</SUP>) day immediately following
the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice; <I>provided</I>, <I>however</I>, that
such restrictions will not be required in connection with the Company&#8217;s issuance or sale of (i)&nbsp;Common Stock, options to purchase
Common Stock or Common Stock issuable upon the exercise of options or any other type of stock-based award, pursuant to any employee or
director stock option or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to
exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii)&nbsp;Common
Stock issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed
in filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii)&nbsp;Common Stock or securities convertible
into or exchangeable for shares of Common Stock as consideration for mergers, acquisitions, other business combinations, license agreements,
collaboration agreements, development agreements or strategic alliances occurring after the date of this Agreement which are not issued
for capital raising purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(i)</TD><TD STYLE="text-align: justify; width: 97%"><U>Change of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice
advise the Agent promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter
or affect in any material respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to
this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(j)</TD><TD STYLE="text-align: justify; width: 97%"><U>Due Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review
conducted by the Agent or its representatives in connection with the transactions contemplated hereby, including, without limitation,
providing information and making available documents and senior corporate officers, during regular business hours and at the Company&#8217;s
principal offices, as the Agent may reasonably request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT></TD><TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Required Filings Relating to Placement of
Placement Shares</U>. </FONT>The Company shall disclose, in its quarterly reports on Form&nbsp;10-Q and in its annual report on Form&nbsp;10-K
to be filed by the Company with the Commission from time to time, the number of the Placement Shares sold through the Agent under this
Agreement, and the net proceeds to the Company from the sale of the Placement Shares pursuant to this Agreement during the relevant quarter
or, in the case of an Annual Report on Form&nbsp;10-K, during the fiscal year covered by such Annual Report and the fourth quarter of
such fiscal year. The Company agrees that on such dates as the Securities Act shall require, the Company will (i)&nbsp;file a prospectus
supplement with the Commission under the applicable paragraph of Rule&nbsp;424(b)&nbsp;under the Securities Act (each and every filing
date under Rule&nbsp;424(b), a &#8220;<B><U>Filing Date</U></B>&#8221;), which prospectus supplement will set forth, within the relevant
period, the amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company
to the Agent with respect to such Placement Shares, and (ii)&nbsp;deliver such number of copies of each such prospectus supplement to
each exchange or market on which such sales were effected as may be required by the rules&nbsp;or regulations of such exchange or market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(l)</TD><TD STYLE="text-align: justify; width: 97%"><U>Representation Dates; Certificate</U>. During the term of this Agreement, (1)&nbsp;on or prior to the
date of the first Placement Notice and (2)&nbsp;thereafter, each time the Company:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;files the Prospectus relating
to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering of securities other
than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective
amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus
relating to the Placement Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii)&nbsp;files an annual report on
Form&nbsp;10-K under the Exchange Act (including any Form&nbsp;10-K/A containing amended financial information or a material amendment
to the previously filed Form&nbsp;10-K);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii)&nbsp;files its quarterly reports
on Form&nbsp;10-Q under the Exchange Act; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv)&nbsp;files a current report on
Form&nbsp;8-K containing amended financial information (other than information &#8220;furnished&#8221; pursuant to Items 2.02 or 7.01
of Form&nbsp;8-K or to provide disclosure pursuant to Item 8.01 of Form&nbsp;8-K relating to the reclassification of certain properties
as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) under the Exchange Act (each date
of filing of one or more of the documents referred to in clauses (i)&nbsp;through (iv)&nbsp;shall be a &#8220;<B><U>Representation Date</U></B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">the Company shall furnish the Agent (but in the case of clause
(iv)&nbsp;above only if the Agent reasonably determines that the information contained in such Form&nbsp;8&#45;K is material) with a
certificate dated the Representation Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar
to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the
Prospectus as amended or supplemented. The requirement to provide a certificate under this <U>Section&nbsp;7(l)</U>&nbsp;shall be automatically
waived for any Representation Date occurring at a time when a Suspension is in effect or there is no Placement Notice pending (the &#8220;<B><U>Waiver
Period</U></B>&#8221;), which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the
sale of Placement Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring
Representation Date for which the requirement to provide a certificate under this <U>Section&nbsp;7(l)</U>&nbsp;is not waived pursuant
to the terms hereof. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation
Date during a Waiver Period and did not provide the Agent with a certificate under this <U>Section&nbsp;7(l)</U>, then before the Company
delivers the instructions for the sale of Placement Shares or the Agent sells any Placement Shares pursuant to such instructions, the
Company shall provide the Agent with a certificate in conformity with this <U>Section&nbsp;7(l)</U>&nbsp;dated as of the date that the
instructions for the sale of Placement Shares are issued.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(m)</TD><TD STYLE="text-align: justify; width: 97%"><U>Legal Opinions</U>. (1)&nbsp;Prior to the date of the first Placement Notice and (2)&nbsp;within five
(5)&nbsp;Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to
<U>Section&nbsp;7(l)</U>&nbsp;for which no Waiver Period is applicable and excluding the date of this Agreement, the Company shall cause
to be furnished to the Agent a written opinion of Gibson Dunn&nbsp;&amp; Crutcher, LLP (&#8220;<B><U>Company Counsel</U></B>&#8221;),
or other counsel satisfactory to the Agent, in form and substance satisfactory to Agent and its counsel, substantially similar to the
form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus
as then amended or supplemented; <I>provided</I>, <I>however</I>, the Company shall be required to furnish to the Agent no more than one
opinion hereunder per calendar quarter; <I>provided</I>, <I>further</I>, that in lieu of such opinions for subsequent periodic filings
under the Exchange Act, counsel may furnish the Agent with a letter (a &#8220;<B><U>Reliance Letter</U></B>&#8221;) to the effect that
the Agent may rely on a prior opinion delivered under this <U>Section&nbsp;7(m)</U>&nbsp;to the same extent as if it were dated the date
of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus
as amended or supplemented as of the date of the Reliance Letter).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(n)</TD><TD STYLE="text-align: justify; width: 97%"><U>Comfort Letter</U>. (1)&nbsp;On or prior to the date of the first Placement Notice and (2)&nbsp;thereafter,
within five (5)&nbsp;Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate
pursuant to <U>Section&nbsp;7(l)</U>&nbsp;for which no Waiver Period is applicable and excluding the date of this Agreement, the Company
shall cause its independent registered public accounting firm to furnish the Agent letters (the &#8220;<B><U>Comfort Letters</U></B>&#8221;),
dated the date the Comfort Letter is delivered, which shall meet the requirements set forth in this <U>Section&nbsp;7(n)</U>; <I>provided</I>,
that if reasonably requested by the Agent, the Company shall cause a Comfort Letter to be furnished to the Agent within ten (10)&nbsp;Trading
Days of the date of occurrence of any material transaction or event, including the restatement of the Company&#8217;s financial statements.
The Comfort Letter from the Company&#8217;s independent registered public accounting firm shall be in a form and substance reasonably
satisfactory to the Agent, (i)&nbsp;confirming that they are an independent registered public accounting firm within the meaning of the
Securities Act and the PCAOB, (ii)&nbsp;stating, as of such date, the conclusions and findings of such firm with respect to the financial
information and other matters ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to underwriters in connection with
registered public offerings (the first such letter, the &#8220;<B><U>Initial Comfort Letter</U></B>&#8221;) and (iii)&nbsp;updating the
Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date
and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such
letter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(o)</TD><TD STYLE="text-align: justify; width: 97%"><U>Market Activities</U>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed
to cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of Placement Shares or (ii)&nbsp;sell, bid for, or purchase Common Stock
in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(p)</TD><TD STYLE="text-align: justify; width: 97%"><U>Investment Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably
ensure that neither it nor any of its Subsidiaries will be or become, at any time prior to the termination of this Agreement, required
to register as an &#8220;investment company,&#8221; as such term is defined in the Investment Company Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(q)</TD><TD STYLE="text-align: justify; width: 97%"><U>No Offer to Sell</U>. Other than an Issuer Free Writing Prospectus approved in advance by the Company
and the Agent in its capacity as agent hereunder, neither the Agent nor the Company (including its agents and representatives, other than
the Agent in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication
(as defined in Rule&nbsp;405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or
solicitation of an offer to buy Placement Shares hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(r)</TD><TD STYLE="text-align: justify; width: 97%"><U>Blue Sky and Other Qualifications</U><I>. </I> The Company will use its commercially reasonable efforts,
in cooperation with the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares
to be offered and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent
may designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement
Shares (but in no event for less than one year from the date of this Agreement); <I>provided</I>, <I>however</I>, that the Company shall
not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction
in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company
will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption,
as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one
year from the date of this Agreement).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(s)</TD><TD STYLE="text-align: justify; width: 97%"><U>Sarbanes-Oxley Act</U>. The Company and the Subsidiaries will maintain and keep accurate books and
records reflecting their assets and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles and including those policies and procedures that (i)&nbsp;pertain to the maintenance of records that in
reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii)&nbsp;provide reasonable
assurance that transactions are recorded as necessary to permit the preparation of the Company&#8217;s consolidated financial statements
in accordance with generally accepted accounting principles, (iii)&nbsp;that receipts and expenditures of the Company are being made only
in accordance with management&#8217;s and the Company&#8217;s directors&#8217; authorization, and (iv)&nbsp;provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have
a material effect on its financial statements. The Company and the Subsidiaries will maintain such controls and other procedures, including,
without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that are
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules&nbsp;and forms,
including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including
its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure and to ensure that material information relating to the Company or the Subsidiaries is made known
to them by others within those entities, particularly during the period in which such periodic reports are being prepared.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(t)</TD><TD STYLE="text-align: justify; width: 97%"><U>Secretary&#8217;s Certificate; Further Documentation</U>. On or prior to the date of the first Placement
Notice, the Company shall deliver to the Agent a certificate of the Secretary of the Company and attested to by an executive officer of
the Company, dated as of such date, certifying as to (i)&nbsp;the Certificate of Incorporation of the Company, (ii)&nbsp;the Amended and
Restated By-laws of the Company, (iii)&nbsp;the resolutions of the Board of Directors of the Company authorizing the execution, delivery
and performance of this Agreement and the issuance of the Placement Shares and (iv)&nbsp;the incumbency of the officers duly authorized
to execute this Agreement and the other documents contemplated by this Agreement. Within five (5)&nbsp;Trading Days of each Representation
Date, unless a Waiver Period is in effect, the Company shall have furnished to the Agent such further information, certificates and documents
as the Agent may reasonably request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">8.</TD><TD STYLE="text-align: justify; width: 97%"><U>Payment of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations
under this Agreement, including (i)&nbsp;the preparation and filing of the Registration Statement, including any fees required by the
Commission, and the printing or electronic delivery of the Prospectus as originally filed and of each amendment and supplement thereto,
in such number as the Agent shall deem reasonably necessary, (ii)&nbsp;the printing and delivery to the Agent of this Agreement and such
other documents as may be reasonably required pursuant to this Agreement in connection with the offering, purchase, sale, issuance or
delivery of the Placement Shares, (iii)&nbsp;the preparation, issuance and delivery of the certificates, if any, for the Placement Shares
to the Agent, including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon the
sale, issuance or delivery of the Placement Shares to the Agent, (iv)&nbsp;the fees and disbursements of the counsel, accountants and
other advisors to the Company, (v)&nbsp;the fees and expenses of counsel to the Agent, payable upon the execution of this Agreement, in
an amount not to exceed $75,000, (vi)&nbsp;the qualification or exemption of the Placement Shares under state securities laws in accordance
with the provisions of <U>Section&nbsp;7(r)</U>&nbsp;hereof, including filing fees, but excluding fees of the Agent&#8217;s counsel, (vii)&nbsp;the
printing and delivery to the Agent of copies of any Permitted Issuer Free Writing Prospectus and the Prospectus and any amendments
or supplements thereto in such number as the Agent shall deem reasonably necessary, (viii)&nbsp;the preparation, printing and delivery
to the Agent of copies of the blue sky survey, (ix)&nbsp;the fees and expenses of the transfer agent and registrar for the Common Stock,
(x)&nbsp;the filing and other fees incident to any review by FINRA of the terms of the sale of the Placement Shares including the fees
of the Agent&#8217;s counsel (subject to the cap, set forth in clause (v)&nbsp;above), and (xi)&nbsp;the fees and expenses incurred in
connection with the listing of the Placement Shares on the Exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">9.</TD><TD STYLE="text-align: justify; width: 97%"><U>Conditions to the Agent&#8217;s Obligations</U>. The obligations of the Agent hereunder with respect
to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein,
to the due performance in all material respects by the Company of its obligations hereunder, to the completion by the Agent of a due diligence
review satisfactory to it in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion)
of the following additional conditions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 97%"><U>Registration Statement Effective</U>. The Registration Statement shall have become effective and shall
be available for the (i)&nbsp;resale of all Placement Shares issued to the Agent and not yet sold by the Agent and (ii)&nbsp;sale of all
Placement Shares contemplated to be issued by any Placement Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 97%"><U>No Material Notices</U>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt
by the Company of any request for additional information from the Commission or any other federal or state Governmental Authority during
the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements
to the Registration Statement or the Prospectus if such post-effective amendments or supplements have not been made and become effective;
(ii)&nbsp;the issuance by the Commission or any other federal or state Governmental Authority of any stop order suspending the effectiveness
of the Registration Statement or the initiation of any proceedings for that purpose; (iii)&nbsp;receipt by the Company of any notification
with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction
or the initiation or threatening of any proceeding for such purpose; or (iv)&nbsp;the occurrence of any event that makes any statement
of a material fact made in the Registration Statement or the Prospectus or any document incorporated or deemed to be incorporated therein
by reference untrue or that requires the making of any changes in the Registration Statement, the Prospectus or such documents so that,
in the case of the Registration Statement, it will not contain an untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will
not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 97%"><U>No Misstatement or Material Omission</U>. The Agent shall not have advised the Company that the Registration
Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable
opinion is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein
or is necessary to make the statements therein not misleading.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 97%"><U>Material Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&#8217;s
reports filed with the Commission, there shall not have been any material adverse change in the authorized capital stock of the Company
or any Material Adverse Effect or any development that would cause a Material Adverse Effect, or a downgrading in or withdrawal of the
rating assigned to any of the Company&#8217;s securities (other than asset backed securities) by any rating organization or a public announcement
by any rating organization that it has under surveillance or review its rating of any of the Company&#8217;s securities (other than asset
backed securities), the effect of which, in the case of any such action by a rating organization described above, in the reasonable judgment
of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable
or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(e)</TD><TD STYLE="text-align: justify; width: 97%"><U>Legal Opinions</U>. The Agent shall have received the opinion of Company Counsel required to be delivered
pursuant to <U>Section&nbsp;7(m)</U>&nbsp;on or before the date on which such delivery of such opinion is required pursuant to <U>Section&nbsp;7(m)</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(f)</TD><TD STYLE="text-align: justify; width: 97%"><U>Comfort Letter</U>. The Agent shall have received the Comfort Letter required to be delivered pursuant
to <U>Section&nbsp;7(n)</U>&nbsp;on or before the date on which such delivery of such Comfort Letter is required pursuant to <U>Section&nbsp;7(n)</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(g)</TD><TD STYLE="text-align: justify; width: 97%"><U>Representation Certificate</U>. The Agent shall have received the certificate required to be delivered
pursuant to <U>Section&nbsp;7(l)</U>&nbsp;on or before the date on which delivery of such certificate is required pursuant to <U>Section&nbsp;7(l)</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(h)</TD><TD STYLE="text-align: justify; width: 97%"><U>No Suspension</U>. Trading in the Common Stock shall not have been suspended on the Exchange and the
Common Stock shall not have been delisted from the Exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(i)</TD><TD STYLE="text-align: justify; width: 97%"><U>Other Materials</U>. On each date on which the Company is required to deliver a certificate pursuant
to <U>Section&nbsp;7(l)</U>, the Company shall have furnished to the Agent such appropriate further information, opinions, certificates,
letters and other documents as the Agent may reasonably request. All such opinions, certificates, letters and other documents will be
in compliance with the provisions hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(j)</TD><TD STYLE="text-align: justify; width: 97%"><U>Securities Act Filings Made</U>. All filings with the Commission with respect to the Placement Shares
required by Rule&nbsp;424 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have
been made within the applicable time period prescribed for such filing by Rule&nbsp;424.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(k)</TD><TD STYLE="text-align: justify; width: 97%"><U>Approval for Listing</U>. The Placement Shares shall either have been (i)&nbsp;approved for listing
on the Exchange, subject only to notice of issuance, or (ii)&nbsp;the Company shall have filed an application for listing of the Placement
Shares on the Exchange at, or prior to, the issuance of any Placement Notice and the Exchange shall have reviewed such application and
not provided any objections thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(l)</TD><TD STYLE="text-align: justify; width: 97%"><U>FINRA</U>. If applicable, FINRA shall have raised no objection to the terms of this offering and the
amount of compensation allowable or payable to the Agent as described in the Prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">(m)</TD><TD STYLE="text-align: justify; width: 97%"><U>No Termination Event</U>. There shall not have occurred any event that would permit the Agent to terminate
this Agreement pursuant to <U>Section&nbsp;12(a)</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">10.</TD><TD STYLE="text-align: justify; width: 97%"><U>Indemnification and Contribution</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
Indemnification</U>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners, members,
directors, officers, employees and agents and each person, if any, who controls the Agent or any affiliate within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading,
or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus
or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount
paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or of
any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <I>provided</I>
that (subject to <U>Section&nbsp;10(d)</U>&nbsp;below) any such settlement is effected with the written consent of the Company, which
consent shall not unreasonably be delayed, conditioned or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">against
any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened,
or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or
not a party), to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided</I></FONT>,
<I>however</I>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out
of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Agent
Information (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 04 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Agent
Indemnification</U>. Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who
signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the
Securities Act or Section&nbsp;20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in
the indemnity contained in </FONT><U>Section&nbsp;10(a)</U>, as incurred, but only with respect to untrue statements or omissions,
or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto), the Prospectus (or any
amendment or supplement thereto) or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) in reliance upon and
in conformity with information relating to the Agent and furnished to the Company in writing by the Agent expressly for use therein.
The Company hereby acknowledges that the only information that the Agent has furnished to the Company expressly for use in the
Registration Statement, the Prospectus or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) are the
statements set forth in the seventh paragraph under the caption &#8220;Plan of Distribution&#8221; in the Prospectus (the
 &#8220;<B><U>Agent Information</U></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Procedure</U>.
Any party that proposes to assert the right to be indemnified under this <U>Section&nbsp;10</U> will, promptly after receipt of notice
of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under
this <U>Section&nbsp;10</U>, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served,
but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any liability that it might
have to any indemnified party otherwise than under this <U>Section&nbsp;10</U> and (ii)&nbsp;any liability that it may have to any indemnified
party under the foregoing provision of this <U>Section&nbsp;10</U> unless, and only to the extent that, such omission results in the forfeiture
of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies
the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects
by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified
party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory
to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense,
the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below and except
for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified
party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will
be at the expense of such indemnified party unless (1)&nbsp;the employment of counsel by the indemnified party has been authorized in
writing by the indemnifying party, (2)&nbsp;the indemnified party has reasonably concluded (based on advice of counsel) that there may
be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying
party, (3)&nbsp;a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified
party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on
behalf of the indemnified party) or (4)&nbsp;the indemnifying party has not in fact employed counsel to assume the defense of such action
or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable time after receiving notice of the commencement
of the action; in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying
party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings
in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local
counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements
and other charges will be reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating
to fees, disbursements and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement
of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified
party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating
to the matters contemplated by this <U>Section&nbsp;10</U> (whether or not any indemnified party is a party thereto), unless such settlement,
compromise or consent (1)&nbsp;includes an express and unconditional release of each indemnified party, in form and substance reasonably
satisfactory to such indemnified party, from all liability arising out of such litigation, investigation, proceeding or claim and (2)&nbsp;does
not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Settlement
Without Consent if Failure to Reimburse</U><I>. </I> If an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for reasonable fees and expenses of counsel for which it is entitled to be reimbursed under this <U>Section&nbsp;10</U>,
such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by <U>Section&nbsp;10(a)(ii)</U>&nbsp;effected
without its written consent if (1)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of
the aforesaid request, (2)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior
to such settlement being entered into and (3)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance
with such request prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing
paragraphs of this <U>Section&nbsp;10</U> is applicable in accordance with its terms but for any reason is held to be unavailable or
insufficient from the Company or the Agent, the </FONT>Company and the Agent will contribute to the total losses, claims,
liabilities, expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and
any amount paid in settlement of, any action, suit or proceeding or any claim asserted) to which the Company and the Agent may be
subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the
Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be
deemed to be in the same proportion as the total net proceeds from the sale of the Placement Shares (before deducting expenses)
received by the Company bear to the total compensation received by the Agent (before deducting expenses) from the sale of Placement
Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable
law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits
referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Agent, on the other hand,
with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in respect
thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or
alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and
their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and
the Agent agree that it would not be just and equitable if contributions pursuant to this <U>Section&nbsp;10(e)</U>&nbsp;were to be
determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or
damage, or action in respect thereof, referred to above in this <U>Section&nbsp;10(e)</U>&nbsp;shall be deemed to include, for the
purpose of this <U>Section&nbsp;10(e)</U>, any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any such action or claim to the extent consistent with <U>Section&nbsp;10(c)</U>&nbsp;hereof.
Notwithstanding the foregoing provisions of this <U>Section&nbsp;10(e)</U>, the Agent shall not be required to contribute any amount
in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within
the meaning of <U>Section&nbsp;11(f)</U>&nbsp;of the Securities Act) will be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. For purposes of this <U>Section&nbsp;10(e)</U>, any person who controls a party to this
Agreement within the meaning of the Securities Act, any affiliates of the Agent and any officers, directors, partners, employees or
agents of the Agent or any of its affiliates, will have the same rights to contribution as that party, and each director of the
Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the
Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim for contribution may be made under this <U>Section&nbsp;10(e)</U>,
will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that
party or parties from whom contribution may be sought from any other obligation it or they may have under this <U>Section&nbsp;10(e)</U>&nbsp;except
to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party
from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of <U>Section&nbsp;10(c)</U>&nbsp;hereof,
no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is
required pursuant to <U>Section&nbsp;10(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><U>Representations and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained
in <U>Section&nbsp;10</U> of this Agreement and all representations and warranties of the Company herein or in certificates delivered
pursuant hereto shall survive, as of their respective dates, regardless of (i)&nbsp;any investigation made by or on behalf of the Agent,
any controlling persons, or the Company (or any of their respective officers, directors, employees or controlling persons), (ii)&nbsp;delivery
and acceptance of the Placement Shares and payment therefor or (iii)&nbsp;any termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><U>Termination</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The Agent may terminate this Agreement, by written notice to the Company, as hereinafter specified at
any time (1)&nbsp;if there has been, since the time of execution of this Agreement or since the date as of which information is given
in the Prospectus, any change, or any development or event involving a prospective change, in the condition, financial or otherwise, or
in the business, properties, earnings, results of operations or prospects of the Company and its Subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business, which individually or in the aggregate, in the sole judgment of the Agent is
material and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the
Placement Shares, (2)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving
a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such
as to make it, in the judgment of the Agent, impracticable or inadvisable to market the Placement Shares or to enforce contracts for the
sale of the Placement Shares, (3)&nbsp;if trading in the Common Stock has been suspended or limited by the Commission
or the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed
on the Exchange, (4)&nbsp;if any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market
shall have occurred and be continuing, (5)&nbsp;if a major disruption of securities settlements or clearance services in the United States
shall have occurred and be continuing, or (6)&nbsp;if a banking moratorium has been declared by either U.S. Federal or New York authorities.
Any such termination shall be without liability of any party to any other party except that the provisions of <U>Section&nbsp;8</U> (Payment
of Expenses), <U>Section&nbsp;10</U> (Indemnification and Contribution), <U>Section&nbsp;11</U> (Representations and Agreements to Survive
Delivery), <U>Section&nbsp;17</U> (Governing Law and Time; Waiver of Jury Trial) and <U>Section&nbsp;18</U> (Consent to Jurisdiction)
hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided
in this <U>Section&nbsp;12(a)</U>, the Agent shall provide the required notice as specified in <U>Section&nbsp;13</U> (Notices).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The Company shall have the right, by giving ten (10)&nbsp;days notice as hereinafter specified to terminate
this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of
any party to any other party except that the provisions of <U>Section&nbsp;8</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;11</U>, <U>Section&nbsp;17</U>
and <U>Section&nbsp;18</U> hereof shall remain in full force and effect notwithstanding such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">The Agent shall have the right, by giving ten (10)&nbsp;days notice as hereinafter specified to terminate
this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of
any party to any other party except that the provisions of <U>Section&nbsp;8</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;11</U>, <U>Section&nbsp;17</U>
and <U>Section&nbsp;18</U> hereof shall remain in full force and effect notwithstanding such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">This Agreement shall remain in full force and effect unless terminated pursuant to <U>Sections 12(a)</U>,
<U>(b)</U>&nbsp; or <U>(c)</U>&nbsp;above or otherwise by mutual agreement of the parties; <I>provided</I>, <I>however</I>, that any such
termination by mutual agreement shall in all cases be deemed to provide that <U>Section&nbsp;8</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;11</U>,
<U>Section&nbsp;17</U> and <U>Section&nbsp;18</U> shall remain in full force and effect notwithstanding such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">Any termination of this Agreement shall be effective on the date specified in such notice of termination;
<I>provided</I>, <I>however</I>, that such termination shall not be effective until the close of business on the date of receipt of such
notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement
Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><U>Notices</U>. All notices or other communications required or permitted to be given by any party to
any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall
be delivered to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">499 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">New York, NY 10022&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Capital
Markets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">499 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">General
Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">55 Hudson Yards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">New York, NY 10001-2157</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Daniel
I. Goldberg,&nbsp;Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">and if to the Company,
shall be delivered to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Rockwell Medical,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">30142 Wixom Road<BR>
Wixom, Michigan 48393</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Russell
L. Skibsted</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Gibson Dunn&nbsp;&amp; Crutcher, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">555 Mission Street, Suite&nbsp;3000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">San Francisco, California 94105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Ryan
A. Murr</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.26in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Each party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each
such notice or other communication shall be deemed given (i)&nbsp;when delivered personally or by verifiable facsimile transmission (with
an original to follow) on or before 4:30&nbsp;p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the
next succeeding Business Day, (ii)&nbsp;on the next Business Day after timely delivery to a nationally-recognized overnight courier, (iii)&nbsp;by
Electric Notice as set forth in the next paragraph&nbsp;and (iv)&nbsp;on the Business Day actually received if deposited in the U.S. mail
(certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &#8220;<B><U>Business Day</U></B>&#8221;
shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">An electronic communication
(&#8220;<B><U>Electronic Notice</U></B>&#8221;) shall be deemed written notice for purposes of this Section&nbsp;13 if sent to the electronic
mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending
Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall
be entitled to receive the notice on paper, in a nonelectronic form (&#8220;<B><U>Nonelectronic Notic</U>e</B>&#8221;) which shall be
sent to the requesting party within ten (10)&nbsp;days of receipt of the written request for Nonelectronic Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">14.</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company
and the Agent and their respective successors and the parties referred to in Section&nbsp;10 hereof. References to any of the parties
contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; <I>provided</I>,
<I>however</I>, that the Agent may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company&#8217;s
consent, so long as such affiliate is a registered broker dealer and the Agent provides advanced notice of such assignment to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><U>Adjustments for Stock Splits</U>. The parties acknowledge and agree that all share-related numbers
contained in this Agreement shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect
to the Placement Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify"><U>Entire Agreement; Amendment; Severability; Waiver</U>. This Agreement (including all schedules and
exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior
and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof.
Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent.
In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid,
illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to
the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed
as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to
such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected
in this Agreement. No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party. No failure or
delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof
preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><B><U>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER
TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL
BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify"><B><U>CONSENT TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION
OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR
IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR
PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS
BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES
PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED
OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES
THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED
TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party
to the other may be made by facsimile or by electronic delivery of a portable document format (PDF) file (including any electronic signature
covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other
applicable law, e.g., www.docusign.com).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify"><U>Construction</U>. The section and exhibit&nbsp;headings herein are for convenience only and shall not
affect the construction hereof. References herein to any law, statute, ordinance, code, regulation, rule&nbsp;or other requirement of
any Governmental Authority shall be deemed to refer to such law, statute, ordinance, code, regulation, rule&nbsp;or other requirement
of any Governmental Authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and
also to all rules&nbsp;and regulations promulgated thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">21.</TD><TD STYLE="text-align: justify"><U>Permitted Free Writing Prospectuses</U>. The Company represents, warrants and agrees that, unless it
obtains the prior written consent of the Agent, which shall not be unreasonably withheld, conditioned or delayed, and the Agent represents,
warrants and agrees that, unless it obtains the prior written consent of the Company, which shall not be unreasonably withheld, conditioned
or delayed, it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing
Prospectus, or that would otherwise constitute a &#8220;free writing prospectus,&#8221; as defined in Rule&nbsp;405, required to be filed
with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is hereinafter
referred to as a &#8220;Permitted Free Writing Prospectus.&#8221; The Company represents and warrants that it has treated and agrees that
it will treat each Permitted Free Writing Prospectus as an &#8220;issuer free writing prospectus,&#8221; as defined in Rule&nbsp;433,
and has complied and will comply with the requirements of Rule&nbsp;433 applicable to any Permitted Free Writing Prospectus, including
timely filing with the Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto agree
that all free writing prospectuses, if any, listed in <U>Exhibit&nbsp;21</U> hereto are Permitted Free Writing Prospectuses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">22.</FONT></TD><TD STYLE="text-align: justify"><U>Absence of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Agent is acting solely as agent in connection with the public offering of the Placement Shares and
in connection with each transaction contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory
relationship between the Company or any of its respective affiliates, stockholders (or other equity holders),
creditors or employees or any other party, on the one hand, and the Agent, on the other hand, has been or will be created in respect of
any of the transactions contemplated by this Agreement, irrespective of whether or not the Agent has advised or is advising the Company
on other matters, and the Agent has no obligation to the Company with respect to the transactions contemplated by this Agreement except
the obligations expressly set forth in this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions
of the transactions contemplated by this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with
respect to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors
to the extent it has deemed appropriate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and the Agent and its affiliates have no obligation to disclose such interests and transactions
to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">it waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates
for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement
and agrees that the Agent and its affiliates shall not have any liability (whether direct or indirect, in contract, tort or otherwise)
to it in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the
Company, employees or creditors of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.</FONT></TD><TD STYLE="text-align: justify"><U>Definitions</U>. As used in this Agreement, the following terms have the respective meanings set forth
below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">&#8220;<B><U>Applicable Time</U></B>&#8221;
means (i)&nbsp;each Representation Date, (ii)&nbsp;the time of each sale of any Placement Shares pursuant to this Agreement and (iii)&nbsp;each
Settlement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 05 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">&#8220;<B><U>Governmental
Authority</U></B>&#8221; means (i)&nbsp;any federal, provincial, state, local, municipal, national or international government or governmental
authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court,
tribunal, arbitrator or arbitral body (public or private); (ii)&nbsp;any self-regulatory organization; or (iii)&nbsp;any political subdivision
of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">&#8220;<B><U>Issuer Free Writing
Prospectus</U></B>&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule&nbsp;433, relating to the Placement
Shares that (1)&nbsp;is required to be filed with the Commission by the Company, (2)&nbsp;is a &#8220;road show&#8221; that is a &#8220;written
communication&#8221; within the meaning of Rule&nbsp;433(d)(8)(i)&nbsp;whether or not required to be filed with the Commission, or (3)&nbsp;is
exempt from filing pursuant to Rule&nbsp;433(d)(5)(i)&nbsp;because it contains a description of the Placement Shares or of the offering
that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required
to be filed, in the form retained in the Company&#8217;s records pursuant to Rule&nbsp;433(g)&nbsp;under the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.26in">&#8220;<B><U>Rule&nbsp;164</U></B>,&#8221; &#8220;<B><U>Rule&nbsp;172</U></B>,&#8221;
 &#8220;<B><U>Rule&nbsp;405</U></B>,&#8221; &#8220;<B><U>Rule&nbsp;415</U></B>,&#8221; &#8220;<B><U>Rule&nbsp;424</U></B>,&#8221; &#8220;<B><U>Rule&nbsp;424(b)</U></B>,&#8221;
 &#8220;<B><U>Rule&nbsp;430B</U></B>,&#8221; and &#8220;<B><U>Rule&nbsp;433</U></B>&#8221; refer to such rules&nbsp;under the Securities
Act Regulations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.26in; margin-bottom: 0pt; margin-left: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
references in this Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221; &#8220;included&#8221;
or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean
and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement
</FONT>or the Prospectus, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">All references in this Agreement
to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy
filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer
Free Writing Prospectuses that, pursuant to Rule&nbsp;433, are not required to be filed with the Commission) shall be deemed to include
the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to &#8220;supplements&#8221; to the
Prospectus shall include, without limitation, any supplements, &#8220;wrappers&#8221; or similar materials prepared in connection with
any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<B><I>Signature Page&nbsp;Follows</I></B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">If the foregoing correctly
sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon
this letter shall constitute a binding agreement between the Company and the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">Very truly yours,</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">ROCKWELL MEDICAL,&nbsp;INC.</TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Russell L. Skibsted</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
  <TD STYLE="text-align: justify; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell L. Skibsted</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">Title:</TD>
  <TD STYLE="text-align: justify">Executive Vice President, Chief Financial Officer and Chief Business Officer</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">ACCEPTED as of the date first-above written:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">CANTOR FITZGERALD&nbsp;&amp; CO.</TD></TR>
</TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sage Kelly</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sage Kelly</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Managing Director and Global Head of Investment Banking</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Placement Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 6%">&nbsp;</TD>
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:</FONT></TD>
  <TD STYLE="width: 84%"><FONT STYLE="font-size: 10pt">Rockwell Medical,&nbsp;Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 6%">&nbsp;</TD>
  <TD STYLE="width: 10%">To:</TD>
  <TD STYLE="width: 84%">Cantor Fitzgerald&nbsp;&amp; Co.<BR> Attention: [&#8226;]</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 6%">&nbsp;</TD>
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:</FONT></TD>
  <TD STYLE="width: 84%"><FONT STYLE="font-size: 10pt">Placement Notice</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 6%">&nbsp;</TD>
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="width: 84%">[&#8226;], 20[&#8226;]</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.51in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0.26in">Pursuant to the terms and subject to the conditions
contained in the Sales Agreement between Rockwell Medical,&nbsp;Inc., a Delaware corporation (the &#8220;<B><U>Company</U></B>&#8221;),
and Cantor Fitzgerald&nbsp;&amp; Co. (&#8220;<B><U>Agent</U></B>&#8221;), dated April&nbsp;8, 2022, the Company hereby requests that the
Agent sell up to $[&#8226;] of the Company&#8217;s common stock, no par value per share, at a minimum market price of $[&#8226;] per share,
during the time period beginning [month, day, time] and ending [month, day, time].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: 0.26in">The Company shall pay to the
Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount of up to 3.0% of the aggregate gross proceeds
from each sale of Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notice Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The Company</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Russell L. Skibsted</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The Agent</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sameer Vasudev</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incorporated by reference to Exhibit&nbsp;21.1 of the Company&#8217;s
most recently filed Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;21</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Permitted Free Writing Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2212156d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%">&nbsp;<IMG SRC="tm2212156d2_ex5-1img003.jpg" ALT="" STYLE="width: 206px; height: 33px"></TD>
  <TD STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="tm2212156d2_ex5-1img004.jpg" ALT=""></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;8, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockwell Medical,&nbsp;Inc.<BR>
30142 S. Wixom Road<BR>
Wixom, Michigan 48393</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rockwell Medical,&nbsp;Inc.</I></FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><I>Registration Statement on Form&nbsp;S-3 (File No.&nbsp;333-259923)</I></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have examined the Registration Statement on Form&nbsp;S-3 (File
No.&nbsp;333-259923) (the &#8220;<U>Registration Statement</U>&#8221;), of Rockwell Medical,&nbsp;Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;),
filed with the Securities and Exchange Commission (the &#8220;<U>Commission</U>&#8221;) pursuant to the Securities Act of 1933, as amended
(the &#8220;<U>Securities Act</U>&#8221;), and the prospectus supplement thereto dated April&nbsp;8, 2022 (the &#8220;<U>Prospectus Supplement</U>&#8221;),
in connection with the offering by the Company of up to $12,200,000 of the Company&#8217;s common stock, par value $0.0001 per share (the
 &#8220;<U>Shares</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In arriving at the opinion expressed below, we have examined originals,
or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of specimen Common
Stock certificates and such other documents, corporate records, certificates of officers of the Company and of public officials and other
instruments as we have deemed necessary or advisable to enable us to render the opinions set forth below. In our examination, we have
assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons,
the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to
us as copies. We have further assumed that all offers and sales of the Shares will comply with the minimum offering price and pricing
formula set forth in the authorization of the offering and sale of the Shares by the Company&#8217;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing, and subject to the assumptions, exceptions,
qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor as set forth
in the Registration Statement and the Prospectus Supplement thereto, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the filing of this opinion as an exhibit to the Registration
Statement, and we further consent to the use of our name under the caption &#8220;<U>Legal Matters</U>&#8221; in the Registration Statement
and the Prospectus Supplement. In giving these consents, we do not thereby admit that we are within the category of persons whose consent
is required under Section&nbsp;7 of the Securities Act or the Rules&nbsp;and Regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">Very truly yours,</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">/s/ Gibson, Dunn&nbsp;&amp; Crutcher LLP</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><IMG SRC="tm2212156d2_ex5-1img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rmti-20220408.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+LybOdzZR+aYkxtmB3balKvyIohp84QSuh2ahm4awF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:rmti="http://rockwellmed.com/20220408" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20220408">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://rockwellmed.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rmti-20220408_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rmti-20220408_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rmti-20220408_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rmti-20220408_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:href="rmti-20220408.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://rockwellmed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2212156d2_ex5-1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212156d2_ex5-1img003.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  A ,X# 2(  A$! Q$!_\0
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M32@[\&=YKGO#_#F<9QC.23R2$JD;1=JE.'*I.6K?VEK=JST;/O.Y^.?P:L?
MEE\5+KXE^#+3X:ZG(+&R\8W&M6UCX=O=0'G*D2ZM*RP*Q;3IU#,Q1EA()8;5
M/"67[9'[+%_?P6MI^T#\*WDNH=EO:S^,-'LWDXQM5IYHU)[@LPZ ^@KU#XLV
MEE+\+/B-9W5M;RV1\"^)A' /FWLVCZD ISDX;!7G&&#\\8K\(/AA\9_@%I'_
M  34U+X7^-9['4O'FO0>.]#\.:%=>'=7$$7CO6M?\0/X+U9M9.B?\(SH<_AX
M&W\3Q/\ \)(R6\5O<D7*231QOZ/"7#66<28&>,A3XIG47%N$X44*#HU?=Q<7
M)5_WD(J=6FDY1G)TXUXQFU.E;7@XAXHS7(<7]4<^%XK_ %7J8C]].K3;JTI<
MME9W=!MOEBK[ZWN?T50&.8_:8Q'-%+'^[E!.Y@1MV #'& <Y!P!DG S7S;XS
M_:T_9T\#Z_K7A3Q+\5O"NF:YH,PL/$-KYFHZDVAWVP$6^M+I$-S_ &*21@FZ
M\D9(+,H!(\Q_80\&>-?"?[('@/PSK_BC2=7UQM+\27/AW5-,\0:)XRTK2],U
MS6=5N-#TV#Q#H(7P_P"(HK(2*&F@+0F0RP.3)$P7XG_8O_:2^%/P[\)ZO^Q]
M^TGHI\&?%.R\7^,-(\477C.U&H^&_B3JWC3Q"\THUSQ QE1-9NXM=6"Z?Q);
MR>%3:-H$<7C6X>6)(^?#<%8?$8GBR-*57B2'#E;EE+A5WOAU4J0GQ8E*A4F\
M/3Y(QB^2\N:+=14[SE6)XJQ/_&)IQAPZ^(K3Y>+(QC)5FE)<*OEE"V(G=MMN
MR4=(REH?M3I>JZ;KNF6.HZ5=VM]I>IVEI>Z;=VK!K.YL7"O&\9Y!22,Y&,<;
M%*K@K7A?CC]J/X _#W7-2\,>*?B?X:TWQ/IMFEQJ^@V\FH^(-4T6 (")=8TG
M0(+Z71P>,"X\G>3D<')^:OVW_B=J?[('[(^D:9\+[JXTS5D7PE\'O FKW.[4
MM0T>T71ITDU9MRJ)];MO#NA:K+ VT#[0JS+M= ![+^QW\//#?P__ &>_AS):
M6-J^M^*O!WAOQGXWUW]W)JGBOQ9XKTN/6]<UG6]8 #ZU+)=:I<&.:5G 104Q
MN7'DOA["T,FCQ)C7*KE%?B:KA.&(QC3C.I*G%.4ZDTG"%2-.M3C&$(.]6NU=
M4X6/:EGN(Q&:3X=P34<WITU5J3EK",6^G>[2L[[);MV?O_P\^*/P[^+&B#Q-
M\./&'AWQGH N9+)M4T'58=2@AU"/RQ+8%TSY; ,N8Y'C//$>/F'%^)?VB_@1
MX3\:2_#KQ#\4O!FD>.VO-*TO_A%M1UF"QU8ZAK/DMH]ND,CJ6-TNHQJFW=S*
M"2A3%?EA^T;J!_8N_;7^#OC_ .&EE'H'@'XY1MHGQ2\'Z8(]+\->(=4_MN/2
M]5UZ#1X42.3Q#;#Q#H.OB>-=PFMI4=Y)?%4DC^^_\%"/@38?'76_V=/!4-S!
MHWBSQ/XH^(VE:3XJ^R(VHV!T3X9^)?'.DZ:TNQ6?19/$?A_1'N5)=1Y:,I\R
M60M]!AN%<I_M/))8_-:N'R#B'#U*WUB4*<JF$5%5(UHUZ24TY4:E-*7)[M2F
MXM*+4K>'B>*<V>"SI8+*5/.\@:BZ=WRU.:W*X/>TXO;H^COK^EFOZ]H_AG1[
M_P 0:W?6NFZ1HUG)>ZKJ5V<)9V,8+,[L 2!D*,G/0DACBO*?A_\ M"?!'XL:
MS=>&?A[\4/!GC+7;*T%_=Z9X?UF'4;ZUL","62.)BX7=@L6VGJ2O&1\7?L5?
MM1>--<U?5_V8/VDGDTKX_P#@:'?:W.I/L7QWX8B*&*>.<,$UCQ!:JKR><I67
MQ;X-AC\;1K))_P )4+7Z,_9>T73=*U3]IM[&U@M5N_VG_'-W=BW4+ND?P;\/
MR6<#'SX"C:, $DCC->-CLC_L.>8X7,E)9E#V%2A5H5:,\-B*59)TZL)P515:
M3I2C5IRI5.6<9I.SU?M9?G\<WAE>+RK6,^=3C-/F5DDXM-JTKW336EMM#ZX!
M"1C/(!)(SST'X\9/]<U\K3_MI_LGV[&$_'_X7!SU">+-*?CK@[)''7^@]Z^H
MG?)\H_QQ,?H<'G\<?U[8/Y+?LR:1IK?\%%/VU6?3=/06^C> S$ZVB!@HM=&+
M'=@C._:1M Y ((7-9</Y7EF;83BC&8QU.;(<+#%*--TDJKEB*%#V<W4A-I)U
MHS3CRZ1E=W<;:9_F6987%Y1@L"H7SBK*DY33?):+J75FOLWOU['Z._#_ .,?
MPK^*UO=W/PX^(7@_QO'ICJM__P (IXBTG6?L98 +_:26EQ-)!\P'55.XC"DX
MJ7XD?%;X9_";3['6/B5XUT+P9IVK77]GV-WK]ZFFV5[?E581J[Y4G.U@'8+@
M@DGY6K\]?^"AWPTT7P/\*+C]I7X4VEK\/OC1\*/$7AG5CXV\,6\.A:KXCT?Q
M!K6D>']9T;Q"(TCA\0B=-2TW$?B<2(JPLI*C*CM_%OQ4;X[_ /!-SQM\3=4M
M;:*]\4?L_>++W6+6R):P3Q-H::YHNL1:<Q!)1/$6D7 M]W1/)SD\GT\+PK2Q
M>#R;.L-=9'GO%L.$)KFB\11Q$E0GRRM!4JBE1K.<91A%7A)27O)KS<5Q-6PF
M*S?)L6HO.LCX1_ULNO@G&]2%EJG93A*+5WH^EC[+^&_QI^%GQ?AU6?X:^./#
MOC.+1&L$U2?P]?Q:BMD=5$CP*[1DA?,CC+KC<J@8< @(.8M/VF/@)>>.C\.+
M?XK>"I_'W]KMX:/A)=9B'B(ZR6)_LHZ./W_G8XSL*\<L>M>7?L#&*U_9!^ X
MBB$*/X55%C[JO]I:F6'KR79NO.[UJ_H>C:7%^VQ\1-3%G;?VA)^S;\+E^U?9
MP7PWQ*^+7F([Y&6N/[(T?;T(&C)MVL%(\S%97E>$SCB?+[5&\DEBX0E>G>3P
ME54VY_N[6J1O-<BC9QY=G==6%S3,\7E/"^,3CS9TJ4JBL_=56FZD;:W]U+7Y
MOR?H6@?M%_ KQ1XZ3X>:#\3_  9K7CY+S4["3PQ9ZW;'Q$;W0S*FKH=&,@N%
M%L-/D=V\L(JQN59@3O[[QQ\0_!/PVT.^\3^.]>TKPIH%I.MO=:OK%X+&R61]
MVT-([ <[3CTP><#)_'[]M7X&^,OB%^U])X@^#=^_ASXK> OV>/#7Q4\*SV+1
MV%OXD\2:/\2_$FA#2KB9R%_M2?0D$4$C9'_$KME=8XRWE_97['W[4NC?M)^!
M-3T7QC9MH7QC\ Q)HWQ:\%W]H^G7"ZJDXTJ35X=(RY.AWDJAY ZO_8,C):W)
M!"._JYGPQA*&291Q)DM2>>933A"7&%*,XPK<(SE4J1I\[<)TY4:[C%4ZBIQI
MPJ34:DXS3@O/P'%6+Q.<9OPYC5"EF[]H^%92C+DKPC!7YG?25._-)-ZPO9.\
M6_>-&_:1^ 6O>%O$GCC1/BGX*U'PCX+73/\ A+?$]KK43:/X?76"HT<ZKJN_
MRHA<!@%9I"1N7?Y9!5ND^'7Q8^%_Q:T[5M1^&WC'P]XVT[3KI[/5;KP_JT6I
M1VM^@4M"S1;]AP20&"@A<KG! \<_8LTG3+']E'X2:7#;0QV#>&;Q(K06X";'
MU?50P*$;>6+#D9[U^,GPLE^)?[&T&G?M8^!]/N?$?P3\7>._''@GXR?#^U"Y
MT--"^*'B+PYH^L1%LLPVJT/A-% #>*KI8I-R>-' ]++>$,FS;%<7X'"9TXYS
MDF(^K\'0J2_=\7N->K3=*,X6=*=6%+FH<WNNK4IPUE)<_)FG%6;Y9A.$<;B\
MH@\ISN$I<6347*6&<Z<91DHN7O14I+F76*>J:NOWJ^(O[0WP4^%&L6?A[XD?
M$[PEX-U>\LGU6UTWQ!K$>F2W.G LAE42E59%8$[0Q8X!",,BO5/#^K:=KNFV
M>MZ/>0WND:S8V6KZ7>V^&2XL-2A^T6\@SU5T(=6P#M8!@K @?$?QM\5> ?CU
M\(_@#\0O"TFF^)_"FO?M$_L\:QH>I2VWFPJ#\5M%T'4_W<B\7"P-J_AZ8,C)
MYDTB!G0*S?>\2I&@3@A< G&<G'^>>^<\9KX?'8/"T<)E[<:BS.^(A5YW!PC[
M*<:5HQ4%+W[RG)2E)))).[T^OR['8O%8[,7[CRM.G[)V]YRDN9N]VEJDMM;[
M+KXI\=_AA%\8/@W\2?A@MW!I\_C/PIJVBV5Y-@BRU*>%SHNI-$ISMMM9$$_&
M6<Q*4!?*G\^?^"<WQ@_X17PS>_LE?%^WD\#_ !<^$NJ:Q8:9HVOWOV%O%/AI
M]5U77 _AUYIP-9A\+PZ@D8BMD5%\*R^&+J1&+S2+^MHRBQKW/.?;/3VKA/&7
MPY^'_CFVBMO'?@KPIXSLX#FULO%7A[2/$<2'G)CBURWN4!.<G'))RQ).:Z<)
MF^%PV09EP]FE-U,FJ58XB,E*,)T:T*3I*JE)<E13I2=*I!ZV2E&TD<>89+6Q
M.;99Q!@[1S:E!TGS:PE2DKN+=[Q2U=[][^7Y'?'KQ!XT\(_M]_!7X/Z'\:?B
M?9?#[XF6>EZWXI\*#X@:I+)IVJ:EJ_B-;?1-(UF)_P#A)O#^A>('TC2H!'!<
MD B7R)HO.95])_X*WZC8V?P4^$4<]Y;VTQ_:!\*7;P-<^6\MD/!GQ!$S;>NT
M?+M.,9W*I8@X_13PK\'/A+X'=)_!/PQ^'7A.X/'VCPOX'\,>'I'/LVBZ/ PQ
M_M?RK3U[X>^ O%-VNI^)_!OA?Q/J,%JUK:W6O>']*U._@LBP9XEEU>&21(]Q
MRX)!&3G[YKZ3!<:93@\XX-Q\LHBX\-QA[:DY48_ZT58U:M=3JRC%+2E55&2M
M=0A&:YG*;?DXOA+%XS*>+L"\U?\ QD+ERRM)JDFE!I)MZ2MTMNUV2Y_XIZKI
MT?PC^(NM'4+%-+_X5WXDN/[2:X3[ (QH^IEY?,#LOEKY>6(+$_= RN*_-+]A
M#QA\%O\ AWY+H?Q/UKPC=>%]+3XG'QSH'B"[T<!=,/B#7=;G$FC%^5,3[XXS
M&<O&S!B5"U^HLO@'P)<:':^#Y_!GA:;PY!_IEMH;>']';0;6]3>8YH]($ M1
M,"S'(@/W^6 P1EVWP8^$5NZS0_##X=P74<;.MU#X)\++..0<"8:0)5QC^&0'
M'0\UXV6YKEN7Y+FF0\E62K<4T.*958U*4)TO8TITH]&U*2<FZD+QA**Y8O1'
M=C<HS/%YQEN<QE!.GPQ5H2B[N]6HXS?6VK:]UZN[Z69^4'_!-'Q!\0/A7^QM
M\:?B)?Z)J>MZ%H=YXE\;?#W0-3N([$ZS#H_@_P#MO5TTIF#F&&]GC,2$K^]>
M&14(,;,OM'[:'A?]G+]H+]C_ ,1_'BU_X15M2'A#3O$OP[^(5M9:+_PDHU55
M5M"\(^:R>9/-<RR-X>F\-O(Y+M(K RJ[U^H'EQ-&;=% M9(044#A6'4XZYSD
M$XY_2O)[7X'?!/3];.O:;\)?ACIWB_S/M8\36GP]\*6?B$WN2?-&MQZ.E\9F
M7Y?-$_F;LX8YR/7Q7&]'&\85>-H98\DSB7%4<?2^K2BHQA#V;]BI2BW*-25)
MOVLK7C5JQE#X.3S,)PA6PG#2X6G+^W,E7"TL)RU5K.I]EQ2=K2BVXJ]]$]'O
M^?\ \5OV<?BW\?O^"=GPN\">)9G?XU>%])\(_$&&VU:9OMVH:UI&DZW;1:3K
MK*IQXB_X1[7-DTARD7B^..21DB0N/</V$_C=X9^)'P-\$>&KR_ATOXD?"OPW
M:_#[QQX,U6>&P\1:7J?@V--"FOI]&9_.CAN7A#B18VCWL%=U(C#?>[HC;@<$
M%0&7';K@?3'^3R?+?$_P6^$7CR;[=XT^%GPX\77RKA-4\4^"/"_B#4E X"BX
MUC1+B1%&0 -Y&.@Q7FXKBBAFV3YGDN:971A&7%53BS#U:5HRP];$0J0JJ,+>
MRJTI0Y/9Q]R=*=!-)J34?3P_#,,MS>.<96_>API#A50;TY*%13HSD]TXR4N;
MNGNK:_F#\>O!\'[9W[9'P?\ !O@34H;[X=?LW6__  D?Q/\ &EKLU3P_)J6K
MZMX>UL>#M&UJ!I(4\1-_8&BE-LFWRV\0A]ESX5:(?6/[1/C'P[H'[17[%VEZ
MEJFG6M]??$/XFW4=M<72*6A3X.>)]#C5 2.1KWB#057=C.[/!) ^NM#\.Z'X
M9L(K#P[I.GZ'I-K;E;/3=,LXK"RM%/#".&%(XEY)R50!CG()R:YS7?AO\/=>
MO9-5\0^!?!^OWPMT^TWVK>%M&U.]FP%50\]S:R7!P<#[Q(P."<FLY\3X::RC
M!U*4HY-D'#5:AAXTY153EQ$:OM<14G)6YJDZLZKC&.D:=.FG)N<GS1X?Q%)9
MOBH2BLVSSB:%:4G?DC"FXQA%)-^[&G36K;O=MI+0^+_VX_V5=;^-6BZ)\5/@
M]??\(I\?/ALYO/!OB/3)QINH:UISDI<>'I=96%#N4AI_##R!HH)9KF)BD7B&
MY=)_^";WC+Q/\1/A)\2/&/CJP&E^-]6^-7B:V\8V8T]M+V^)M!\'^ _#^K*N
MFCF/]YI! 3YB<9 !&3^A\44,$(ACC"0QC"*.% P22,'H,C.>H[>F-I6A:+I,
MFI7&E:3ING/K6IRZMJCZ?9169U#4)1 7U'5&2)'FU1RD8>:7,\A5?,.5!2?]
M9,;B^%UPYCHPE&,X3I57%>UIQYI3GA^=KF=!U)>VC'F:C4;]W52CUKA;!X;B
M)\282ZE*+C..T7=<JE9/E4K:-KI;5V=]IE(&>RQ,O_?0/KSW],&OQY_9Q\<>
M$=-_X*.?MAV%[XATC3KG6M&\)#24O]7TJT-__8EMHD.N#3%+B254=T>8L68E
M"Q((WK^PLT$-S%+!/&LL-PN)XI@'1E(&5*L",  $ DC@8(KRB3X&_!:=BK_"
M3X8S$=?-\">%''N.=&/X=/;'6N?(\VPV5X3.,+B(SD\_PZH>Y.G%PBJ]/$*5
MJB:G*]*,5'16;=[V-\YR?$9EC,HQF%E&+R2K*I%2WDW#D<5;LNO=;6W^"OV]
MO'.G_%SP+:_LH_!B2Q\=_%?XN^(O#NGWUKHETVH:9X(\,Z!KNB>(-:\0>,]9
MT&61_#D,8TS3XT$FV1Q*3@(L;/[M-^SC>^#/V(=>_9R\/7;:SX@M/@KXM\)V
M=Y!;II_]L>)]<T?7)-^Q6=8TFU_5/,SNW*&4N%+,H^I?#_AOPMX6MY(/#'A[
M1O#EB8"ZV>AZ7I^E0@E@I(ATF*&,,#W49R.QKIQ=@-L(!/V?SCD'DGD$CKW'
MMQ^-=L.**U#)\IR'*6J>39%Q:^,53YH2JU.+8>Q@Z]1QBN5PC&--0B].9N<V
MVE'E_P!788C&YMF^;+_A6SO"?ZKN4/@AAES-1AJ[W;E)O1-)'YH?\$V_CQX'
M\4?LY>&OA]>ZM!HGC;X/6U]X>\5^'_$%U#IVHVPAUO5UTK5=KRQNVB7<2-Y,
MH!1"FQVCPHE]Y^$>M6OQ'_:"^-/Q.T.6WU/P5HGA/X;_  <TGQ!9R07]EK_B
M3P]K7C[QKXXFTG5XRBW&B^'W\>:!X;/EJ5CU#2?$*8(56/M&N_ [X+>*]0&N
M>*_A#\,_$NO@#&KZ_P" O"VM:IG.%V:IK.A2SM[G=QT(Z5Z9IVG6.CV<&FZ5
M96NFV%I&+>UM+*T6SM+:-02JQQH %4YZQC#-R<DDUCF^;99C,;F^/P>63I//
M*DYNG*I"I&E[62J55&2A&4HOWHT^=+DA-O5J/+>39-FF$P64X+&9I&;R.,8N
M48<KFHQ<8<SO;1/5MN]DO(^ [3Q!I(_X*2ZKH']IZ?)?-^R!H]F]JUPOG+J,
M/Q9U[54TXQGY2XTC58[@8R/+VG;QM'A'[;7P%^)7P\\?6_[9/[,T5UI_C_PM
M:;?BAX6TFQ::/QSX;B2.7^U)M(6W@35Y8]V[Q3NS)/9I;WGG&3PP@/Z>?\*O
M^'*ZZGB,^!/!A\0G4_[=.N?\(IHW]JG5RVP:K_:QLC/_ &N3_P O?FBYZ -M
M!)]!RA>3)Y09#8^Z,\@<]/;/7IP>-<+Q9/*,TRO'8"44GPG2X5Q5#$3I3I\1
MT>6K4Q"J*"7,JJFZMM>2I&%2+M"3?-B>$J>9X;,L'CI7OQ:N*:4H\Z:DI0=.
MSN]5[)*_573U:M\C?L57Z7/[)/P9U>[6&VCE\#/=3J3A+8/J.I%^><!?F7/9
ME;&<<>9?L#7?@_X@?LPZSH\\.C>(=&N?B+\8=.\0Z?<E-2L;W3O$7CC7M=6+
M5@Z,C&?0=:@1ED 1OER?3[:C\(>%(/#A\%P>&M"A\*II_P!B'AH:/I:Z!]C+
M!O*.D+#]E\DX *&+RR?F,>[D4O#_ (+\%>$9+Q_"WA#PQX;FN+<)=7&@^']*
MTI[L @_O'TNWA=EXR1*3TY -+$YKA\5#BZI[.:?%'%,>*I252'+1Y*N(JI-*
MTI-O$OWH^ZO9Q=KMM=^$RC$8-Y/[T;9'PQ[!.S]ZHXTX=7I94K[?,_"[Q%\,
M/BM^Q_\ M"_"WX+V%S-XA_9F^,'[0OPD\6^!Y;\FY/A#Q'HGQ,\/^()=$%P"
M9(-;E:-)?,#%_& 52ZK-&Z+_ $&PGK(%P7 R3W[]OSZUS>JZ'HGB"&RAURPL
M-5@L-3T[5+2"^MH[TV>J:/*-3TO4H4EB9H=5MI%AFCE0K)'M3RW*EA)T=NZL
M6P<H!@ CIZ?US67$_%?^L\\IK8V5.EFL:56&*Q:E",^(Y\RJ?6JB:O.K[-0=
M64?>;IQG)V=B^'>'H</RS&E@G;+*LXRH0]Z\6FTTNEE?3HDVK71=HHHKP3Z,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2212156d2_ex5-1img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212156d2_ex5-1img004.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 (L# 2(  A$! Q$!_\0
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M^%?ACXT9_$'A3PY\5Y/#]MX;U3QMHP\'7FCZGK&B_%?7M5TGQMX?\1O:>+/
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MDB$'C0FZ\8^%?!O@XM\//%03QG&MQX-'BSN?A+^U'HOQ9\96O@G_ (5C\3_
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2212156d2_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2212156d2_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  C DX# 2(  A$! Q$!_\0
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M\)O!?A+PMXP\;>,?^$4U;Q/XYAA'@GQ3XQD\(?JMX[_9L^$/Q+^.?P)_:/\
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ML/?M%Z/H_@S5="\7?!GP[KW@CP?^R_\ "7_A&O UGJG@[3M=^%O[./@WX[Z
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M:#XRUSX@Z1HC^#1KQ\)B1?$^M3LOB!/"[^*G"1V[70MGD1?@3X\_\$GO@O\
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MO?A=;_#KQAX$^)FD_%#XN:M\(X_$7@_XF?#*?2_"WB?1?AO\0OB)JZ2B?Q%
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M;>#_ !EK<[Q))X?\1/\ &[1O%W@3XC1RPP>+OA^GASQK#$L?BBUCC^U/C+X
M7XJ?"'XK_"V'5?[$N/B1\._&_@,:H+4:A_8A\;:#K6@?VO\ V9N!F:+^UGF*
MG'FA KD1J]?G/^T#_P $PM#^//Q!UGX@+\4=4\$3>)_V0;[]F_Q%IEAX;?4M
M(U'Q]I7Q3^!'Q3^'_P 9UT4^(Q'+KOA9_@=%X4\9^&O,9_&_@V7PMX/D\86M
MOX2BD(!]6Z=^V_\ LH:AI5QKJ?'WX?)I&G>&=8\;3W5[J::4NF^%="\6>'O
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M[.O[-^I?"3PG\1_ ?C+Q+X<\;>$_&]_&;'X<Z!H?B^Q^$G@+PX?!^C>']?\
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MQ/\ V@/"?Q'UCXE>"KGP3X ^*?AGXK>"(=1^%4;_ !J^'#Z)X-T3P]KWPO\
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MPP_;J^,\?Q>UI!HDGQ+A3_A8OPHUS11H7@SQ*SGP=XN@8_:O T)98CUFA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139668836868680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  08,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rockwell Medical, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142
S. Wixom Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom, Michigan
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm2212156d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20220408.xsd" xlink:type="simple"/>
    <context id="From2022-04-08to2022-04-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-08to2022-04-08">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-08to2022-04-08">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-04-08to2022-04-08">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-08to2022-04-08">2022-04-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-04-08to2022-04-08">Rockwell Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-08to2022-04-08">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-04-08to2022-04-08">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-08to2022-04-08">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-08to2022-04-08">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-08to2022-04-08">Wixom, Michigan </dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-08to2022-04-08">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-08to2022-04-08">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-08to2022-04-08">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-08to2022-04-08">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-04-08to2022-04-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-04-08to2022-04-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-04-08to2022-04-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-04-08to2022-04-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-04-08to2022-04-08">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-08to2022-04-08">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-08to2022-04-08">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-04-08to2022-04-08">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &"EB%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !@I8A4<H:V@N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R'&[PDR:RT9/'0Q6V-C-V&IK&L?&UDCZ]G.R-F5L#["CI=^?
M/H%J':3V$5^B#QC)8KH;7-LEJ<.:'8F"!$CZB$ZE,B>ZW-S[Z!3E9SQ 4/JD
M#@B"\Q4X)&44*1B!19B)K*F-ECJB(A\O>*-G?/B,[00S&K!%AQTEJ,H*6#-.
M#.>AK>$&&&&$T:7O IJ9.%7_Q$X=8)?DD.R<ZON^[!=3+N]0P?OS]G5:M[!=
M(M5IS+^2E70.N&;7R6^+QZ?=AC6""U'P9<$?=IS+I9#WJX_1]8??3=AY8_?V
M'QM?!9L:?MU%\P502P,$%     @ 8*6(5)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !@I8A4EXJ[',
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MZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " !@I8A4)!Z;HJT
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M2P$"% ,4    " !@I8A4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &"EB%1RAK:"[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M &"EB%297)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 8*6(5!Z7KAE$!   11   !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M &"EB%2?H!OPL0(  .(,   -              "  8@,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ 8*6(5)>*NQS     $P(   L              ( !
M9 \  %]R96QS+RYR96QS4$L! A0#%     @ 8*6(5*K$(A8S 0  (@(   \
M             ( !31   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &"E
MB%0D'INBK0   /@!   :              "  :T1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &"EB%1ED'F2&0$  ,\#   3
M          "  9(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  -P3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2212156d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2212156d2_8k.htm">tm2212156d2_8k.htm</File>
    <File>rmti-20220408.xsd</File>
    <File>rmti-20220408_lab.xml</File>
    <File>rmti-20220408_pre.xml</File>
    <File>tm2212156d2_ex1-1.htm</File>
    <File>tm2212156d2_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2212156d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2212156d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20220408_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20220408_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rmti-20220408.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20220408",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2212156d2_8k.htm",
      "contextRef": "From2022-04-08to2022-04-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://rockwellmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2212156d2_8k.htm",
      "contextRef": "From2022-04-08to2022-04-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-22-044376-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-044376-xbrl.zip
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M)YK+-6PU0#./[OJ-&CFW4S?WE]K[UAU-[DYI"WRDW_9SXO-EJWNYDUFGXK"
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MW/Q%VF3V-;R5/#N] UCF>BZCM[D> V$&1*DQHA,O.?-.RL2(S4-GCN_LLHO
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M3-83NR0X!?NOUHOZ%F\E[HU(7 H];"DQG<JS66[^RN:X/](!$S>$/DB/2BG
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M\KN2Q4C&]A+2 I^A%B":0T<PHI2K;_D,T]XATH1&81+1T @R1(0J>]?@($1
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M#'<M05_7MK"/&V+@KYP_LP=4K9 T1>T*$'W:VEID3RU*&H"H37*^$52A:%$
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M5B1IREUSM9Q4"Q4?KWY^\SP '[9$AW4N% R3U <) \](284#7!1O*0Y:\0W
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M>'0MFII1PH('[G?GI= 9%&_&[BN^4"N5S$1&]*,<!BX[LNU.,3YY-,D6Q#C
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M+)GD[24&>X;I?$4](S'$>1F(Q=(LC(3P70QLBDN=CT=];,1]M[A/VR\;#X)
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M^ ,%T2G-!H&]@50P;?/6G(86$^%$!T\/#D"?;A#UEF6+J3X"8Q6E+F6+JZ!
M;BN]7 <;^YGY9^_?NF+5%7O_UA7[-Q'X\_E[%O@_H!NZ=KK;#_D:;(&-\";
MV#J"PJ"R-HU1,>@_%2^$+YOGN,U<>XID,G5,F/O52 .D579E?8R#.KC GXD"
MF9]S12R^K2?)KRM3^T(.N8$ \B5Z%L DQ%[Z9)CK;;3AX.SL/5^BG\ Z!J7M
M:=&LNM9=H"I9X.=H=[8="F=@T8P:/N,'F?"03*NK?)@O5XUW.2.Z;:Q5YZRX
MONZ8AOEN07G-QP1=_=E3X?GY>Z9";J)*[@\E(= "K\?-"R:N;([H :!VHN;+
M?A$"%FAW*3_&I&A09[%2K%0EN/!SG7JC4, '/!::/.TA O4I[("W;K34*=Z-
M59;1O6/<*CC;^*[A6DZ^N7^'W)O4=1;=>/A\K_^-_MB[?V7/ Q?>QW6)/MVR
M_:)XSW?H!?6E0TW"AXLK]]DV&<U$8^PI4=>@!\'&"J[% JX0;?'Z#H,V&(/A
MQN1MGJ_TOOGX3 "-JO,CV,,I3_ '29Q\8]6D5S[HYJC]JX#:V6?*$&2+C'P<
M9/XB8J$ B:*1^EM7%\VLD&%=SXE(QOM@DZ3)MC3P6N-Q\5X65R=$P1=IXRQJ
MXC E%+\]ZXI9OL#4/A2$38<+RV;+HB1@%!Y!*H%FPE5&DNDW=\/ZF3;K)[]9
MG&T9\H)' @$;M)&1$B!M=(+S0" XLM3&T_NI%7RUN.AU(%JG.,14W>BT.:(^
M;/$3%"0':H;7,6[9W0VQN]]^>]_L;CX_>IPMB/^\/L\18JZN,^FOTECWKW04
ML[86XOS[AXTOKK:01A@(;"\)OK6<?8FD"3SEK,]&OPQIU@ 6ZXWO2L2+0Q<-
M77Q6$#:B.E/6)B&Z=@2*Q$PU3SG9 VL@V=''297\._U(=) #])ZF1G?ARS[<
M.L-@^Y<^,7&4-0AW$E0Q$?U8?&51 ,?7)EB4L7F1 0>4'!1L\%0/ +/W]W!;
MIXP<C@R@ZH#C-6;_)+Z\=ED1E'WO.'7S,U$X"AK^/,BZ(5-IV@D.%1SP:9DM
MKK W&:+M.KGW!.1FX:O<7OE6 %Y,)P>O."$9[*WF.+EWCT)A7]]Y\/!1<N\^
M_7'_P3W4!']X17\]/#E,0Y2L2;ZV[Y/!,7' QO[YS#N<;]N8?GH<]NW;]\EA
M'9_]%44KMI< [NA<2)&,1 ?[S-W5)+/+-_>2P!9\(G4FG1_8N]F8"RO6&0=I
M&:/>&%EH4Q5EAPGY E!N>/NM!+\A^EHL/@A]/7OU_/6IP$:]V:2H4330!4W5
M_02,K03+N$U6"]S""/@=C!. .-\[N-=#;=:A7N6M")_]O><EX2I)0H(QKK^Z
M'QK7@71U"PKA^A4;73-%8]H\.0N*22<RE8OFO7D^JFC@[3&^N%H#IJ/^N768
M!2Y,[F=*D3JW[7W##T<0'X7K]A,:=KUXMAIBJ52ZI6MBUE;,3[ X/523$MIM
M]^+GFK_Q*K_(RPX7S&@$)]]\_7"#0P0?'5H\):5#GQ<3?J'G,RDGYFX@M/L<
M/N99PL&$7W[SU0-_,K.<X?^KJ40BQMR=[B!,F*('+Q5+LN4*^05ZJ-XYQ<DJ
M2+FD; :A@TQ.JZJ9_H1B486YH&SOY<JE&C,;ISOJ7Z9T+R:SRU+KN+>(.?G!
MWIW<M;LSV#X,T>O>$B"7B@W8P"7WOV#<<VYKI3!1QKT6-BP9?[.[$AHEHBY=
M)*I@4DB1EQF6O/F2\'E6U$%S%>?;EO1I[7[I-^K 'XMDP8%FZ(+YL*BZ0SL?
MM-*N)-PYQRWP] XI4I3/&HWY8["?7ZW^#N&2F!DA@[%CPD_!()=U#7MH? 4
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M_H0D5))W6,FPM<>S=U,0+6<Y)Y4J>U7J$6Z._$<@URBR,,L1DZ(H'=\@H<@
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M^"[OQ> >3 5 6H4T(K+A"BF5F73GN<;,68K%=O"6<+<FW-^OB6&5O%!PFM?
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MA(UF;F<:<,8@XP&)X[4*_:.*FURQAG=K:.X]^,]B-H$SCZ7"&N4$%'!Q6_;
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M&!SV@G.5DDIYQ?Q550:LK6PY5U[F6K/J.8HL(;$$[4*N&$ 9EE?BEV'Z,&)
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M*#-4);[^%YP1>A[#($82["/P/%^F E-4VKK.O?N0NBF-5CF7R^(5VKNM5^@
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M;K$K65@#.V.'O9HS0X=*/0PMB>,XF21322^BVZ!K+'36>72%H033NJ+% WT
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M!1 _1* -ET9%/-A^]1NUCZKY^^O;XX//!!-Y?_KQ _SC_P-02P,$%     @
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M14XLHBF1"'G$?)YQ7^KM#BM E?C;<I%9@6GH'X68P1!:R@O\! W,0C=SAP=
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MQ?ZQA?XF\Q=02P$"% ,4    " !@I8A4KE/333T#  #^"P  $0
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M2P$"% ,4    " !@I8A4X2A=I(&U  "D"@0 %0              @ &X+0
M=&TR,C$R,34V9#)?97@Q+3$N:'1M4$L! A0#%     @ 8*6(5$]H/P9!!P
MFAD  !4              ( !;.,  '1M,C(Q,C$U-F0R7V5X-2TQ+FAT;5!+
4!08     !@ & (L!  #@Z@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
